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Ab antibody
Ag antigen
ADCC antibody-dependent cellular cytotoxicity
APC antigen presenting cell
BCR B cell receptor
BSA bovine serum albumin
CD40L CD40 ligand
CFSE carboxyfluorescein diacetate, succinimidyl ester
CγC common gamma chain
CTL cytotoxic T lymphocyte
CTLA-4 cytotoxic T lymphocyte antigen 4
DC dendritic cell
DNA deoxyribonucleic acid
FACS fluorescence activated cell sorting
FCS fetal calf serum
FDC follicular dendritic cell
GC germinal center
GFP green fluorescent protein
HA hemaglutinin
H chain heavy chain
IFN-γ interferon-γ
Ig immunoglobulin
IL interleukin
int intermediate
kDa kilodalton
KO knock-out
LAG-3 lymphocyte activation gene-3
LN lymph node
LPS lipopolysaccharide
mAb monoclonal antibody
8MHC major histocompatibility complex
MT promoter metallothionein promoter
MZ mariginal zone
neg negative
NFAT nuclear factor of activated T cells
NF-kB nuclear factor kappa B
NK natural killer
o/n over-night
OVA ovalbumin
PAGE polyacrylamide gel electrophoresis
PCR polymerase chain reaction
pDC plasmacytoid dendritic cell
PHA phytohaemagglutinin
poly(I)-poly(C) polyriboinosinic acid polyribocytidylic acid
RAG recombination activating gene
RBC red blood cell
RNA ribonucleic acid
RT room temperature
RT-PCR reverse transcription - polymerase chain reaction
SDS sodium dodecyl sulfate
SEB staphylococcal enterotoxin B
sLAG-3 soluble LAG-3
TCR T cell receptor
TD T cell dependent
TI T cell independent
Th helper T lymphocyte
Treg regulatory T cell
TLR Toll like receptor
TNFα tumor necrosis factor α
ΤNFβ tumor necrosis factor β
WT wild-type
9SUMMARY
Lymphocyte activation gene-3 (LAG-3) is the structural homologue of a well-known
TCR co-receptor CD4. Recently, it has been suggested that LAG-3 might play a role in
modulation of immune response, by being a negative regulator of T cell activation.
To further characterize its expression and function in the immune system, monoclonal
Abs were generated against mouse LAG-3. The availability of different mAbs allowed
the identification of LAG-3 on various immune subpopulations.
The main finding of this work is that, unlike previously thought, LAG-3 expression is not
limited to activated T and NK cells, but can also be induced on B cells and DCs. B cells
were found to express LAG-3 in a T cell dependent manner; LAG-3 was expressed on B
cells in the presence of activated T cells, but not upon stimulation with thymus
independent stimuli like CpG or LPS.  Furthermore, requirements for LAG-3 induction
on B cells were defined; this event requires B cells proliferation and is mediated by a
soluble factor released by activated T cells.
Among DCs, two populations, CD8- (‘myeloid’) and plasmacytoid DCs, expressed high
levels of surface LAG-3 upon stimulation with LPS and CpGs, respectively.
To evaluate the potential role of LAG-3 in APC function, LAG-3 deficient and OT-II
transgenic mice were used. Antigen presentation assay showed, that LAG-3 presence on
the surface of APC can affect T cell responses. T cells stimulated with OVA peptide
presented by LAG-3 deficient B cells proliferated poorly compared to T cell stimulated
with OVA-pulsed LAG-3 positive B cells. This finding suggests a novel co-stimulatory
function of LAG-3 on APCs.
In addition, experiments re-evaluating published data concerning the role of LAG-3 on T
cells were performed. In agreement with previous reports, the ectopic expression of
LAG-3 on the surface of T cell line exerted an inhibitory effect on T cell activation
induced by relevant antigen. However, in disagreement with recent report (by Huang et
al. 2004), the standard regulatory cell assays performed with normal as well as LAG-3
deficient CD4+CD25+ cells, suggested no involvement of LAG-3 in regulatory T cell
function.
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Furthermore, the experiments demonstrating the surface expression on murine CD4 and
CD8 T cells in vivo are presented. LAG-3 was identified on homeostatically expanding T
cells after transfer into lymphopenic mice.
To investigate structural aspects of the LAG-3 molecule, soluble LAG-3 (sLAG-3),
composed of four extracellular domains was produced. For this purpose Drosophila
expression system was employed. The conditions were developed for production of two
forms of sLAG-3, the original glycosylated form and its non-glycosylated version.
Biochemical analysis of soluble protein showed that in solution LAG-3 forms stable
dimers, which suggests the presence of such dimers on cell surface. Because
heterogenous glycosylation of WT form likely prevents protein crystallization, attempts
are now made to crystallize non-glycosylated form of sLAG-3 alone or in complex with
its ligand, MHC class II. The detailed structural information would significantly enhance
our knowledge about LAG-3 and allow for rational drug design, if desired.
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1. INTRODUCTION
1.1 The Immune System
The immune system of our body is responsible for protection against the myriad of
potentially pathogenic microorganisms that inhabit the world we live in. It is an
organization of cells and molecules with specialized roles, which work around the clock
in many different ways.
In an adult organism, the cells of the immune system originate in the bone marrow, where
many of them also mature. Others, like T cell progenitors, need to migrate to the thymus
to undergo maturation. They then leave these primary lymphoid organs to patrol the
tissues by circulating in the blood and in a specialized structure called the lymphatic
system. Organized lymphoid tissues such as lymph nodes (LN) and spleen as well as
Peyer’s patches of the intestine and tonsils, called secondary lymphoid organs, are the
place where the initiation of the adaptive immune responses occurs. Various
macromolecules or any foreign substance (such as virus, bacteria or protein) able to elicit
immune responses in the body are termed antigens. The responses to antigens present in
the lymph are mounted in lymph nodes while the spleen is a site of the induction of
immune responses to antigens in the blood stream.
There are two fundamentally different arms of the immune system: the innate and the
adaptive responses. Both are tightly linked and work in concert to eliminate the pathogen.
The innate immunity is the less specific component, which provides the first line of
defense against infections. Most of its ‘weapons’ are present before the onset of infection
so it can act very fast.  It has the property of pattern recognition, an ability to recognize a
class of molecules unique to microbes.  Phagocytic cells (such as macrophages and
neutrophils), anatomic barriers (such as skin and mucous membranes), physiologic
factors (temperature, low pH, chemical mediators) and a variety of antimicrobial
compounds synthesized by the host, all play important roles in innate immunity.
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The adaptive immunity is aimed at the particular antigen, but the primary response takes
longer (five to six days) to develop. It involves the proliferation of antigen-specific B and
T cells, which occurs when the surface receptors of these cells recognize the relevant
antigen.  Specialized cells display the antigen to lymphocytes and collaborate with them
in the response to antigen. The adaptive immunity possesses the remarkable property of
memory manifested by faster and stronger attack upon secondary encounter with the
antigen that induced the primary response. It is also capable of discriminating self from
non-self (the foreign particle) or altered-self (a cell infected by a virus or a cancerous
cell), which prevents it to be aggressive against the own tissue.
1.1.1 Players of adaptive immunity
The key players of adaptive immunity are B cells and T cells. For a proper immune
response, however, they need assistance from Antigen Presenting Cells (APCs).
B cells produce Immunoglobulins (Igs, also called antibodies), and manage humoral (that
is pertaining to extracellular fluid) immunity, while T cells are non antibody-producing
lymphocytes and constitute the basis of cell-mediated immunity.
1.1.1.1 B lymphocytes
B lymphocytes are generated in the bone marrow and migrate to the periphery as short-
lived and functionally immature cells. Through the blood stream they reach the spleen
where they develop into long-lived mature B cells (Carsetti et al., 2004; Rolink et al.,
2004). Each B cell expresses a unique antigen binding receptor  (B- cell receptor or BCR)
on their surface. BCR is a membrane-bound Ig molecule consisting of two identical
heavy (H) chains and two identical light (L) chains that are held together by disulfide
bonds and non-covalent interactions. It is associated with two trans-membrane proteins
Ig-α and Ig-β, which are crucial for triggering downstream signaling pathways. Each
chain of the antibody folds into a series of compact domains of similar structure, the so-
called immunoglobulin fold (Ig fold). This structure of approximately 110 amino acids
consists of a “sandwich” of two β-pleated sheets, each containing anti/parallel β strands,
which are connected by loops of various lengths (Frazer and Capra, 1999).
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When a naïve B cell first encounters its specific antigen, the binding of the antigen to the
BCR causes the cell to divide rapidly and undergo differentiation into antibody-secreting
B cells (also called plasma cells) and memory B cells.
Depending on the nature of antigen, the B-cell activation proceeds by two different
routes: thymus dependent (TD) or thymus independent (TI). TD antibody responses to
protein antigens require antigen-specific T cell help in the form of surface molecules’
interactions as well as secretion of soluble factors. Microbial antigens with repetitive
determinants (like lipopolysaccharides, polysaccharides, lipoprotein A) can stimulate
naïve B cells on their own and thus are thymus independent. The TI antigens can be
further divided into two groups: TI-2 antigens, which are multivalent molecules able to
crosslink BCR, and TI-1 antigens activating B cells independently of BCR, acting
through Toll-like receptors (TLRs).  TI-1 antigens, for example LPS, can cause the
polyclonal proliferation and differentiation of many B cells regardless of their antigenic
specificity.
Mature B cells can be subdivided into at least 3 groups: B2 B cells, B1 B cells and the
mariginal zone B cells;
- B2 B cells
B2 B cells, the conventional B cells, constitute the majority of B cells found in spleen and
lymph nodes. This pool of B cells is constantly replenished by differentiation of
progenitor cells in the bone marrow (Rolink et al., 2004). B2 B cells produce high affinity
antibodies after they have been stimulated, expanded and selected in germinal centers in
the presence of T cell help (Carsetti et al., 2004; Fagarasan et al., 2000). They can give
rise to memory B cells as well as plasma cells.
- B1 B cells
B1 cells arise before B2 cells and compose about 5% of B cell population. B1 B cells,
originally defined by the surface expression of CD5 molecule and high levels of IgM,
have a capacity for self-renewal (Herzenberg et al., 1986; Marcos et al., 1989). They are
dominant in the peritoneal and pleural cavities, rare in the spleen and extremely rare in
lymph nodes (Forster et al., 1991; Hayakawa et al., 1985; Herzenberg and Kantor, 1993).
They exhibit different variable heavy chain repertoire and Ig specificities, compared to
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B2 cells (Fagarasan et al., 2000).  B1 B cells are the source of so-called natural antibodies
that are pre-existing or produced during early phase of infection. These antibodies, that
appear to be produced in a T-cell independent manner (Fagarasan and Honjo, 2000), tend
to have a low affinity and broad specificities (Carsetti et al., 2004; Lalor and Morahan,
1990). B1 B cell subpopulation recognizes common bacterial pathogens and plays an
important role in mucosal immunity. But the antibodies produced by B1 B cells often
react to self-antigens (Berland and Wortis, 2002; Fagarasan et al., 2000).
- mariginal zone B cells
Mariginal zone (MZ) B cells are the B cells residing in the splenic mariginal zone, the
junction of white and red pulp.  They have a distinct surface phenotype, including higher
expression of complement receptors and IgM (Oliver et al., 1997). MZ B cells play an
important role in T-independent antibody responses (Fagarasan and Honjo, 2000). They
more rapidly express activation markers and co-stimulatory molecules than conventional
B cells. In some aspects they resemble peritoneal B1 cells. They participate very early in
immune responses and are very sensitive to LPS stimulation, which can induce their rapid
differentiation into plasma cells (Martin and Kearney, 2000; Oliver et al., 1997).
1.1.1.2. T lymphocytes
T cells also derive from cells of the bone marrow, but their precursors migrate to the
thymus gland to mature. During maturation a T cell comes to express the T cell receptor
(TCR) on its surface.  And it is in the thymus, where the T cells-to-be learn how to
distinguish self from non-self, and where the useless cells (the cells not able to recognize
anything) are eliminated (von Boehmer et al., 1989).
Unlike BCRs, TCRs are produced only as transmembrane molecules. A TCR unit
consists of α/β or γ/δ heterodimer in complex with CD3 components. Only as such it can
play its role in T cell activation.  The antigen-binding site is formed by the combination
of N-terminal Ig-like domains of the α/β or γ/δ dimers, while C-terminal Ig-like domains
are constant for each type of TCR chain. CD3 complex consists of the CD3 γ, δ and ε
chains associated with a homodimer of ζ chains or a heterodimer of ζ and η chains and
provides the connection to the intracellular signalling machinery.
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In contrast to BCR, which can recognize antigen alone, αβ TCR can recognize it only in
the form of antigenic peptides that are bound to the major histocompatibility (MHC)
molecules, polymorphic glycoproteins found on cell membrane. The ability of T cells to
recognize antigen exclusively in the context of MHC is called MHC restriction. When a
T cell encounters its specific antigen presented by MHC, it proliferates and differentiates
into effector T cells and memory T cells.
− αβ T cells
There are two well defined subpopulations of αβ T cells: helper T cells and cytotoxic
cells and two less well defined subpopulations of regulatory T cells and natural killer T
cells.
- Helper T cells
Helper T cells (Th) express the CD4 glycoprotein surface molecule and thus are also
known as CD4 T cells. CD4 is an accessory molecule (often called co-receptor)
facilitating interactions of T cells with MHC class II, due to its specific affinity for MHC
class II molecules. CD4 T cells can recognize the antigen only when it is presented in the
MHC class II context (in other words, they are MHC class II restricted). The antigenic
peptides presented on MHC class II derive mainly from exogenous proteins acquired by
endocytosis.
Besides stabilizing T cell- MHC class II bearing cell interactions, CD4 molecule may
mediate signal transduction, thereby promoting the subsequent functional responses. CD4
T cell activation is tightly controlled; by MHC class II restriction and by limiting the
expression of MHC class II on the cells of the body. MHC class II is expressed only on
specialized cells, called antigen presenting cells (APCs).
After a T helper cell recognizes and interacts with peptide-MHC class II complex it gets
activated and gives rise to a clone of effector cells that secrete various cytokines. These
cytokines play an important role in activating other cells that participate in the response.
They are needed for optimal protection and they may also reduce allergic and
autoimmune responses (Delves and Roitt, 2000; Gately et al., 1998; Grunig et al., 1997).
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The differences in pattern of cytokines produced by CD4 T cells result in distinct
responses. Based on the cytokines they produce, CD4 effector T cells fall into two
functional categories: Th1 and Th2. The Th1 cells produce Interleukin-2 (IL-2),
Interferon-γ (IFN-γ) and Tumor necrosis factor β (TNFβ) that have an effect on the
production of opsonizing and complement-fixing antibodies, activate macrophages,
support inflammation and activate T cells. Th2 response, on the other hand, involves the
production of IL-4, IL-5, IL-6, IL-9 and IL-13 and induces strong antibody responses,
favors eosinophil differentiation and activation, but inhibits phagocytic cells (Abbas et
al., 1996; Mosmann et al., 1986; Romagnani, 2000). But more cytokine patterns are
possible; T cells expressing Th1 as well as Th2 cytokines have been designated as type 0
(Th0), while T cells producing high amounts of TGFβ have been termed as type 3
(Th3)(reviewed in (Romagnani, 2000).
- Cytotoxic T cells
Cytotoxic T lymphocytes (CTLs) express the CD8 co-receptor in the form of αβ
heterodimer or αα homodimer, and therefore are also called CD8 T cells. CD8 molecule,
by binding to MHC class I, serves as a cell-cell adhesion molecule and as enhancer of
signal transduction. CD8 T cells are MHC class I restricted and since MHC class I, unlike
MHC class II, is expressed virtually on all nucleated cells of the body, any cell can mark
itself as a CD8 cell target. These cells display peptides derived from intracellular proteins
on their surface in the context of MHC class I all the time. A cell becomes a target when
a foreign, for example viral, peptide is presented on the cell surface. Under the influence
of Th1 derived cytokines, a CD8 T cell recognizing an antigen- MHC class I complex
proliferates and differentiates into an effector cell. CTL can kill the infected cell in at
least two different ways; (1) perforin/granzyme pathway or (2) Fas receptor-mediated
pathway (Delves and Roitt, 2000; Kagi et al., 1994).
- Regulatory T cells
Regulatory T cells (T regs) represent the minor subpopulation of T cells that are thought
to perform a specialized role in controlling both the innate and adaptive immunity (Maloy
and Powrie, 2001; Maloy et al., 2003; Sakaguchi et al., 2001). They are able to actively
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suppress self-reactivity of lymphocytes or their excessive response to pathogen, both of
which can cause damage to the host (Sakaguchi et al., 2001). Specifically, T regs include
those that are able to suppress naïve T-cell proliferation in vitro and to control CD4+ and
CD8+ T cell numbers in vivo in lymphopenic host (O'Garra and Vieira, 2004).
There is no clear-cut definition of suppressor cells, but in recent years the evidence has
accumulated that CD4+ CD25+ cells can perform such a function. The CD4+CD25+
subset of T cells represents 5-10% of the CD4+ T lymphocytes in healthy human and
mice. Their development and function depends on the forkhead/winged transcription
factor Foxp3. Foxp3 is restricted to Tregs and is expressed in these cells irrespective of
their state of activation. Moreover, it was demonstrated that ectopic expression of Foxp3
confers suppressor function on peripheral CD4+CD25- T cells (Fontenot et al., 2003;
Hori et al., 2003). In contrast, the induction of CD25 expression by stimulating CD4+
CD25- cells with anti-CD3, mitogens, or specific antigen does not render the stimulated
cells suppressive (Shevach et al., 2001).
T regs require TCR triggering in order to be suppressive in vitro. But, although their
activation is antigen specific, once activated these cells inhibit both CD4+ and CD8+
responses in an antigen non-specific manner (Takahashi et al., 1998; Thornton and
Shevach, 2000).  Interestingly, the suppression of T cell proliferation by T regs does not
involve killing of the responder cells and is mediated through a cell contact dependent
mechanism (Maloy and Powrie, 2001; Shevach et al., 2001). The cell surface molecules
involved in T reg - T responder interaction, however, remain to be characterized.
Furthermore, regulatory cells do not prevent the initial steps of responder T cell
activation (the expression of early activation markers is not affected), but the activated
cells fail to proliferate due to cell cycle arrest at the G0/G1 stage (Thornton and Shevach,
2000).
- NK T cells
Natural killer T cells (NK T cells) are a distinct population with certain phenotypic
characteristics of NK cells (see below), but also express CD4 and intermediate levels of
TCR with a highly restricted repertoire of specificities. These cells recognize antigen
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presented by the non-classic MHC molecule CD1 and may have an immunoregulatory
role, because they can secrete IL-4 and IFN-γ (Burdin and Kronenberg, 1999).
− γδ T cells
In human and mice,   γδ T cells represent a small percentage (less than 5%) of the
lymphocytes in the thymus and peripheral lymphoid organs such as lymph nodes and
spleen and in circulation), but they are a major population (up to 70%) in the mucosal
epithelia (Hayday et al., 2000).  During development in the thymus γδ T cells appear
before αβ T cells. They are recruited and expand in response to various infections in
humans and rodents (Bukowski et al., 1999). The vast majority of γδ T cells are CD4 and
CD8 negative (Fisher and Ceredig, 1991). γδ TCRs are of limited diversity and can
recognize unprocessed ligands and even nonproteinacious phospholigands directly,
without a requirement for presentation on MHC (Kaufmann, 1996). The role of γδ cells
in the immune system, however, is still enigmatic.
1.1.1.3. Antigen Presenting Cells
Antigen Presenting Cells (APCs) are specialized cells characterized by the expression of
MHC class II on their surface and the ability to deliver co-stimulatory signals required for
T cell activation. APCs include Dendritic Cells (DCs), macrophages and B cells.
T cells require two types of signals from APC for activation and subsequent
differentiation into an effector cell. First one is an antigen-specific signal provided by
interactions between the TCR and antigenic peptide presented by MHC molecules on
APC. The second signal (co-stimulation) is antigen-independent and mediated by
engagement of the T cell surface molecule CD28 with the members of B7 family (like
B7-1/CD80; B7-2/CD86) on the APC.
Molecular events leading to T cell activation occur in a so-called immunological synapse
between T cell and APC (Figure 1.1). This synapse has a complex supramolecular
structure containing many different cell surface proteins whose individual functions are
not yet completely understood.
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- Dendritic Cells
Dendritic cells are ’professional’ antigen presenting cells, i.e. they are specialized for the
uptake, processing, transport and presentation of antigens to T cells. They are sparsely
distributed in non-lymphoid tissue, but have a distinct migratory capability (Hart, 1997;
Matzinger, 1994; Steinman, 1991). Recruitment of DCs from the bone marrow into
peripheral non-lymphoid tissues as well as migration of mature DCs from the periphery
into the lymphoid tissues are coordinated by chemotactic cytokines (chemokines).
Chemokines interact with corresponding receptors on DCs (Hackstein and Thomson,
2004).
     
Figure 1.1 Overview of a mature T cells synapse. The key ligand pairs and signaling
molecules that are involved in T cell recognition are shown. The MHC molecule
presenting the stimulatory peptide is shown in red, activating molecules are blue, B7
family surface molecules in pink, inhibitory molecules are yellow and molecules that are
not contributing to signaling are shown in grey (Huppa and Davis, 2003).
DCs arise from the bone marrow progenitor cells or blood monocytes and differentiate
into immature DCs (Banchereau et al., 2000). At ‘immature ‘ stage of development DCs
act as sentinels in peripheral tissues or circulate in blood continuously sampling the
environment. They are already capable of antigen uptake and processing, but yet are
unable to activate T cells due to low level of expression of surface MHC class II
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molecules and lack of expression of co-stimulatory molecules (Shortman and Liu, 2002)
((Hackstein and Thomson, 2004). At the encounter with the ‘danger’ signal (for example
microbial products or tissue damage), the antigen processed and displayed on the DC
surface as peptide MHC complex is stabilized by decreasing MHC class II turnover, and
the maturation and concomitant migration of DCs to LN takes place. On the way,
maturing DCs down-regulate endocytic activity and up-regulate the co-stimulatory
molecules that are required for effective interactions with T cells (like CD40, CD80 and
CD86) (Banchereau et al., 2000; Cella et al., 1997). This process is accompanied by the
production of inflammatory cytokines, such as IL-12 and TNFα  (Hackstein and
Thomson, 2004). DC maturation can be elicited by numerous stimuli; (1) by endogenous
factors that are released by necrotic cells (for example, heat shock proteins), (2) by
exogenous microbial products including lipopolysaccharide, LPS, peptidoglycans or CpG
rich DNA, that bind to Toll-like receptors (TLRs) or other pattern recognition receptors,
(3) by pro-inflammatory cytokines that are produced by bystander cells (like TNFα), and
(4) by activated T cells expressing ligands for co-stimulatory molecules, like CD40
ligand (CD40 L/ CD154) (reviewed in (Hackstein and Thomson, 2004)).
After migration to the LNs, the mature DCs efficiently trigger an immune response by
activating T cell with the receptor specific for the foreign peptide-MHC complex present
on the DC surface (Shortman and Liu, 2002). In addition to the interactions with T cells,
DCs interact with other cell types including B cells and NK cells present in the lymphoid
organs. Alternatively, DCs might also remain in peripheral tissues and act as mediators of
inflammation.
Besides the insult-induced migration, DCs show continuous low-level migration from
periphery to LNs. These DCs are not activated and, since immature DCs trigger T cell
anergy rather than activation, they probably contribute to the peripheral tolerance of T
cells (Inaba et al., 1998; Probst et al., 2003).
DCs are not a homogenous population, but comprise of at least five different subtypes
related to their origin, differentiation state and their specific location. The functional
significance of this heterogeneity is currently under intense study.
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1.1.1.4. Natural Killer Cells
Natural Killer (NK) cells are another class of lymphocytes that posses a potent cytolytic
activity. Because they lack antigen specific receptors, NK are defined as a component of
the innate immune system, but they were also shown to participate directly in adaptive
immune responses, mainly by interacting with dendritic cells (Raulet, 2004). Also, NK
cells produce a number of cytokines, especially IFN-γ, and therefore are important for
immune regulation and influence both innate and adaptive immunity.
NK cells destroy infected and malignant cells. To identify target cells NK cells use less
specific broad-spectrum receptors (Wang et al., 1997), one kind of which are the Fc
receptors. Fc receptors on the surface of NK cells link them to antibody (IgG) coated
target cells, which are then killed by a process called antibody-dependent cellular
cytotoxicity (ADCC). The second system of recognition involves the killer-activating and
killer-inhibitory receptors. The killer-activating receptors recognize a number of different
molecules present on the surface of nucleated cells, whereas the killer-inhibitory
receptors recognize MHC class I molecules (Moretta et al., 1997) (Lanier, 1998). If the
activating receptors are engaged, the NK cell becomes cytotoxic, but this signal is
normally overridden by an inhibitory receptor upon recognition of MHC class I molecule.
Cells without MHC class I on their surface (the loss of which can be a consequence of
viral infection or malignant transformation) are unable to activate inhibitory receptors
and thus are killed (Moretta and Moretta, 2004).
1.1.2. Lymphocyte homeostasis
In an adult mammal the total number of lymphocytes remains steady throughout an
animal’s life, thanks to a “return tendency, due to a density-dependent process to
maintain a stationary distribution of population densities” (Hanski, 1999), usually
referred to as homeostasis (Freitas and Rocha, 2000; Marrack et al., 2000).
New lymphocytes are continually being produced in primary and secondary lymphoid
organs, and old or useless cells are continually being eliminated (Rathmell, 2004).
Because the potential to produce new cells exceeds the number needed to replenish
peripheral pools, the new cells must compete with resident ones for survival signals and
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resources (Freitas and Rocha, 2000). Since each lymphocyte has a different Ag–binding
receptor, the decision about which cell survives and which dies shapes the repertoire of
the immunocompetent cells. Thus the homeostatic control of cell number provides one of
the mechanisms of lymphocyte selection.
The homeostatic control of cell number is also important after the antigenic challenge.
After an infection, there are bursts of cellular proliferation, but once the infectious agent
is eliminated, the number of cells returns to the state before the infection (Gaudin et al.,
2004). This is a result of death of most of the activated cells, with a small fraction
surviving as memory cells. The number of long-lived memory cells also must be limited
in order to preserve the diversity of repertoire (Grossman et al., 2004).
The mechanisms of such immunoregulation are complex and act at different stages of the
immune response. Both membrane-bound molecules (receptors, co-receptors) and soluble
factors (cytokines) are involved in homeostatic regulation.
1.1.3. T cell responses
There are 4 steps to the T cell response; activation - during which the cell receives
‘instructions’ in the form of antigenic stimulation, followed by a burst-like expansion (the
numbers of activated cells increase rapidly), which after reaching a plateau (upon antigen
clearance) eventually decreases - contraction, a process accompanied by a massive cell
death and memory cell development.
The engagement of TCRs and co-stimulatory proteins on the surface of T cells leads to
activation.  Signal transduction pathways associated with T cell activation include
cascades of kinase signalling, Ca2+ -mediated and small G -protein mediated pathways
(Lin and Weiss, 2001). The combination of those initiates proliferation of cells and
makes them receptive to stimulatory signals delivered through IL-2 receptor. They also
induce production of cytokines such as IL-2 (June et al., 1990), which act in an autocrine
fashion to support further division of activated cells (Marrack et al., 2000).
The activated T cells differentiate into a variety of cell fates. For example, CD8 T cells
become CTLs, capable of killing virus-infected cells. CD4 T cells polarize toward Th1 or
Th2 and mediate protection from intracellular or extracellular pathogens.
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Yet, activated T cells are short lived. The process of elimination of effector cells is driven
by several different pathways, among them, two well-known pathways leading to
apoptosis: Fas-FasL (Ettinger et al., 1995; Van Parijs and Abbas, 1996) or tumor necrosis
factor (TNF) receptor (Sytwu et al., 1996; Zheng et al., 1995) and another way triggered
by reactive oxygen species produced within the activated cell (Hildeman et al., 1999).
Other control mechanisms include (1) competition for growth and viability signals (the
production of cytokines by activated lymphocytes and APCs decreases once antigen is
eliminated)(Ahmed and Gray, 1996) (Freitas and Rocha, 2000), (2) competition for
access to APCs or peptide-MHC ligands (Grossman et al., 2004), (3) elimination of APC
by cytotoxic T cells (Wong and Pamer, 2003), and (4) suppression by specialized
regulatory cells (Maloy and Powrie, 2001; Shevach, 2000).
Interestingly, the rapid disappearance of activated T cells during the contraction phase
does not affect the number of naïve nor memory cell pools (Marrack et al., 2000).
Only 5-10% of antigen specific population survives the contraction phase of primary
immune response and is maintained indefinitely for years (Masopust et al., 2004). These
memory cells provide immediate protection and generate more rapid and effective
responses when again encountering the antigen (Ahmed and Gray, 1996; Dutton et al.,
1998; Zinkernagel et al., 1996).
The regulation of T cell activation and effector T cell expansion during immune
responses is essential for maintenance of T cell homeostasis.
Many surface molecules have been identified that participate in the activation of a T cell;
such as CD28, OX 40, 4-1 BB, LFA-1 and CD2 (reviewed by (Marrack et al., 2000)
(Watts and DeBenedette, 1999)), but few are known that are important for termination of
activatory signals.
A well-documented example of a molecule important for down-regulation of T cell
responses is cytotoxic T lymphocyte antigen 4 (CTLA-4/CD152)(Krummel and Allison,
1995; Walunas et al., 1994).  This immunoglobulin superfamily member is an inhibitor of
the CD28- B7 co-stimulation pathway (Oosterwegel et al., 1999). While CD28 is
constitutively expressed on both activated and naïve T cells (Gross et al., 1990), CTLA-4
is absent in naïve T cells, but is readily detectable on the cell surface within 24 hrs of
stimulation, with maximal expression at 2-3 days post-stimulation (Lindsten et al., 1993;
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Linsley et al., 1992) (Linsley et al., 1992). After appearing on the cell surface CTLA-4
competes favourably with its homologue CD28 for B7 molecules on APCs, because of a
significantly higher avidity for B7 (Greene et al., 1996; van der Merwe et al., 1997).
CTLA-4 deficient mice show a strong phenotype. Their T cells proliferate massively,
which leads to enlarged lymph nodes and spleen, multiorgan lymphocytic infiltration and
death within 3 to 4 weeks after birth, showing that indeed CTLA-4 is vital for
lymphocyte homeostasis (Tivol et al., 1995; Waterhouse et al., 1995).
Recently, another molecule was identified and suggested to play an inhibitory role in T
cell activation - Lymphocyte Activation Gene-3. Characterization of LAG-3 surface
molecule is the topic of this thesis (for detailed information on Lymphocyte Activation
Gene-3 see section 1.2).
1.1.4. T cell-B cell collaboration in B cell responses
The cooperation among the components of the adaptive immunity is absolutely required
for efficient antibody production in response to antigenic challenge.
Ag-specific B cell - T cell interactions occur within defined areas of secondary lymphoid
organs, namely the edges of the T and B cell zones (Garside et al., 1998; Goodnow,
1997). In the white pulp of the spleen, T cells are arranged in the T-cell area around a
central arteriola and make up the periarterial lymphatic sheath (PALS). B cells collect in
the primary follicles surrounding PALS and in the mariginal zone, external to the follicles
(Timens, 1991; Witmer and Steinman, 1984).
According to the two-phase B cell activation model it is the second phase of the B cell
activation cascade, characterized by the germinal center reaction, that is T cell dependent.
The initial Ag-specific B cell activation is induced in secondary lymphoid tissues, by
binding of antigens to the BCR. At the same time as initial activation and clonal
expansion of B cells takes place, T cell activation and expansion occurs driven by their
interactions with professional APC, that provide all signals necessary for T cell
stimulation (Baumgarth, 2000) (Figure 1.2, Phase 1).
Because DCs very efficiently focus and transport antigens from peripheral tissues to T
cells zones of secondary lymphoid tissues, and are potent activators of T cells
(Banchereau and Steinman, 1998), it is generally thought that T cell are initially activated
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by DCs in response to tissue localized antigens, while splenic B cells may be the
initiating APC for blood-borne antigens (Mills and Cambier 2003).
Naïve B cells do not collaborate effectively with T cells, but antigen encounter prepares
them to activate T cells and to receive T cell-derived help signals. Within minutes after
BCR triggering, BCR-antigen complex is internalized and antigenic peptide presented in
the MHC class II context (Siemasko and Clark, 2001). Concomitantly, B cells increase
the expression of cell-surface molecules important for productive interaction with T cells,
including CD80/CD86 (B7.1/B7.2) and MHC class II.  Antigen-specific B cells then
move to the edge of the follicles and undergo cognate stimulatory interactions with
antigen activated T cells. The B cells subsequently become primary antibody forming
cells (AFCs) or precursors destined for the germinal center (GC) (Figure 1.2, Phase II)
(Manser, 2004)
Besides Ag peptide-MHC complex – TCR interplay, several membrane molecules are
involved in the generation of TD humoral responses, of which a TNF receptor family
member - CD40 interaction with its ligand-CD40L (CD154) plays the pivotal role. CD40
is constitutively expressed on mature B cells and upon aggregation triggers a number of
intracellular signaling pathways leading to clonal expansion, germinal center formation,
affinity maturation, and generation of long-lived plasma cells (Bishop and Hostager,
2001; Garside et al., 1998). Interestingly, the CD40L is expressed at high levels primarily
on the surface of activated T cells particularly following CD80/86 mediated CD28 co-
receptor signaling. This demonstrates, that CD40 signal transduction is tightly regulated
by ligand availability and normally occurs after B cells have encountered cognate
antigens and contacted antigen-specific CD4+ T cells (Mills and Cambier, 2003).
Activated B cells can reciprocally trigger cognate T cells to clonally expand and
differentiate (Quezada et al., 2004). It was shown that the induction of optimal levels of T
cell priming to a protein Ag requires the involvement of Ag-specific B cells (Constant,
1999).
Although contact-mediated signals are critical for productive T-B cell collaborations, T
cells produce soluble factors that are important for B cell differentiation as well. One of
the best characterized of these cytokines is IL-4. It enhances B cell survival, primes them
for MHC class II signaling, increases expression of co-stimulatory molecules and
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prepares them for maturation steps (Nelms et al., 1999). Other T cell-derived cytokines
involved in B cell differentiation include IL-2, IL-3, IL-6 and IL-10 (Mills and Cambier,
2003) (Coffman et al., 1988). The B cell responsiveness to the cytokine signals, however,
was shown to occur only after stimulation of their cell membrane molecules by activated
T cells (Bartlett et al., 1990).
Figure 1.2. Helper T-cell regulated B-cell differentiation. The response begins with
migration of activated DC to the LN and triggering of naïve T cell (Synapse I). At the
same time B cell get activated either by soluble antigen or antigen-bearing DC. Following
clonal expansion, antigen activated T cells contact antigen-specific B cells at the
follicular border (Synapse II). At this point B cell undergoes one of two differentiation
options, either to become short-lived plasma cell and progress into T cell area or to form
secondary follicle in the B-cell zone.  The interaction involving germinal center (GC) Th
cells and GC B cells (Synapse III) is critical for late stages of B cell development leading
to formation of high affinity antibody producing plasma cell and memory cell.
Adapted from M.G. Mc Hayzer-Williams, Current Opinion in Immunology
 (McHeyzer-Williams, 2003).
The last phase of TD response, the GC reaction, begins when GC precursor B cells
migrate back to a follicle and rapidly proliferate within the environment provided by
follicular DCs (FDCs).  In spite of their name FDCs are not related to the T zone DCs.
They are specialized stromal cells possessing the ability to hold the antigen on their
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surface in an unprocessed form for very long periods of time (Park and Choi, 2005; Liu et
al., 1996a).
The events occurring in GC (Figure 1.2, Phase III) are described in more detail below.
- Germinal Center reaction
TD B-cell stimulation continues within germinal centers. There, B cells undergo somatic
hypermutation with affinity maturation, resulting in secretion of antibodies with an
increased affinity for antigen, as well as Ig class switching (Berek et al., 1991; Jacob et
al., 1991; Liu et al., 1996b).
During B cell proliferation in the follicle, in the so-called dark zone, the gene segments
coding for the antigen-binding site of the antibody are mutated at high frequency,
resulting in the generation of diverse progeny (Manser, 2004). This process, called
somatic hypermutation, greatly contributes to antibody diversity (Brenner and Milstein,
1966) (Tonegawa, 1983). The rapidly dividing B cells of the dark zone are termed
centroblasts and are characterized by low surface BCR. They then exit the cell cycle and
migrate to FDC-rich GC area that also contains CD4 T cells, termed the light zone. The
light zone B cells, called centrocytes, will die unless are provided with survival signals by
FDC that retain antigen on their surface (Rajewsky, 1996; Wagner and Neuberger, 1996).
Only the centrocytes, which express mutant BCRs with high affinity for the antigen
survive (this process is termed affinity maturation). Later they re-enter centroblast pool or
process and present antigen to GC T cells. The latter results in the induction of H chain
class switching, and differentiation to antibody secreting plasma cells or to long-lived
memory cells (Manser, 2004). The mature naïve B cells express surface Ig of the IgM
and IgD class (Pernis and Forni, 1976), the class switch recombination (CSR) however
leads to the production of Abs that are better suited to achieve certain biological
function(s). During CSR immunoglobulin heavy chain constant gene segment Cµ is
replaced by Cγ, Cε and Cα, switching immunoglobulin isotype from IgM to IgG, IgE and
IgA, respectively (Honjo et al., 2002). IgM, besides representing the major membrane-
bound form of immunoglobulin expressed by mature B cells, is mainly secreted (as a
pentamer) in primary immune responses, it activates complement and phagocytic cells.
IgG is the most abundant class in serum, it is the major type of Abs secreted during
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secondary immune responses. IgA (a dimer or tetramer) is predominant in external
secretions such as milk, saliva, tears and gastrointestinal tract mucous. It is a first line of
defense at mucous membrane surfaces, which are entry sites for most pathogenic
organisms. IgE activates mast cells and basophils via Fc receptors. This class is important
for parasite immunity, but also can cause allergies. No biological function has been
identified for IgD yet.
1.2. Lymphocyte Activation Gene-3
1.2.1. Identification and the predicted structure
Lymphocyte activation gene - 3 (LAG-3 /CD223) was first identified as a cell surface
molecule selectively expressed in activated human NK and T lymphocytes (Baixeras et
al., 1992; Triebel et al., 1990). Interestingly, it was found to be related to CD4 at both
gene and protein level. The two genes are located next to each other in human and mouse
genomes (on chromosome 12 in human and chromosome 6 in mice). Actually, Lag-3
gene is located within the enhancer region of the CD4 gene. Furthermore, CD4 and LAG-
3 have a very similar intron/exon organization. It has been, therefore, suggested that they
might have evolved from the common ancestor (Huard et al., 1994a). The overall amino
acid sequence similarity of LAG-3 with CD4 is barely above the background level
(< 20% sequence identity) but there are notable patches of identity with stretches of
amino acid sequences and the two proteins probably share structural homology at their
four extracellular Ig-like domains (Figure 1.3). However, their cytoplasmic regions
clearly have diverged (Huard et al., 1994a; Triebel et al., 1990). The amino acid
sequences of intracellular tails of CD4 and LAG-3 are compared in Figure 1.4.
Mouse LAG-3 shows 70% protein sequence identity to its human homologue. All
putative structurally important residues are well conserved thus predicting the same
folding pattern (Mastrangeli et al., 1996). Also, the RGD motif in D1 domain is
conserved in human and mouse. RGD motif can be recognized by integrins and thus
modulate cell adhesion (D'Souza et al., 1991). The mouse LAG-3 cDNA and protein
sequence, including all the special features of LAG-3 are shown in Figure 1.5.
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Figure 1.3. The predicted structure of LAG-3 is very similar to the structure of CD4.
Both proteins contain four immunoglobulin-like domains, a stretch of hydrophobic
transmembrane residues and a cytoplasmic tail. The LAG-3 molecule is slightly bigger
with predicted molecular weight of 70 kDa, as compared to 55 kDa of CD4. The amino-
terminal domain, D1, of LAG-3 contains a unique looplike insertion.
Figure 1.4. The amino acid sequences (one letter code) of the mouse intracellular tails of
LAG-3 and CD4. The LAG-3 tail is longer and does not contain the lck binding site. Yet
it has three distinguishable motifs: potential serine phosphorylation site (light blue),
KIEELE motif (red) and Glutamic acid-Proline (EP) rich region (in pink). All three
motifs are conserved between human and mouse (Mastrangeli et al., 1996).
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Figure 1. 5.  Coding sequence of Lag-3.  Coding sequence for leader peptide is indicated
in blue, domain 1- dark green, domain 2 – magenta, domain 3 – cyan, domain 4 – orange,
connecting peptide –black, transmembrane region – red, intracellular part –light green,
non- coding sequence is shown in grey. Extra loop of D1 domain is underlined in black.
RGD motif is underlined in red. Potential glycosylation sites overlapping with human
counterpart are indicated with double asterisk. Single asterisk marks glycosylation site
specific for mouse LAG-3.
*
*
*
*
*
*
*
*
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Human LAG-3 has four potential N-glycosylation sites, Asn-X-Thr/Ser, where X can be
any amino acid residue except for Pro (reviewed by Yan et al. (Yan and Lennarz, 2005)).
The immunoprecipitation experiments on human activated T and NK cell lysates showed
that 70 kDa LAG-3 specie is indeed glycosylated. Upon N-glycosidase F treatment
mobility shift from 70 kDa to 60 kDa was observed (Baixeras et al., 1992). Mouse LAG-
3 protein sequence contains five potential N-glycosylation sites, of which 3 (Figure 1.5)
overlap with human counterparts (Mastrangeli et al., 1996), but so far there have been no
reports that any of them is used.
The close relationship between LAG-3 and CD4 has been strengthened by the
demonstration that both share the same ligand, which is MHC class II molecules on the
surface of antigen presenting cells (APC) (Baixeras et al., 1992).  However, LAG-3 was
shown to bind MHC class II with much higher avidity (at least 100 fold) suggesting that
it might act as natural competitor of CD4 (Huard et al., 1995; Workman et al., 2002b).
This notion was supported by experiments showing that LAG-3 can interfere with MHC
class II-CD4 interaction (Hannier et al., 1998; Huard et al., 1996; Huard et al., 1995;
Huard et al., 1994b), although LAG-3 and CD4 binding sites on MHC class II do not
overlap (Baixeras et al., 1992).
Most of the residues that are essential for interactions with MHC class II proteins are
clustered at the base of the extra-loop structure in the LAG-3 D1 domain. The deletion of
the loop itself also affects MHC class II adhesion. D2 domain is required for successful
LAG-3 – MHC class II interactions as well. It is either involved in the binding itself, or in
positioning of D1 for interaction. Domains 3 and 4 were found to be dispensable for
binding to MHC class II (Huard et al., 1997).
Interestingly, unlike CD4, LAG-3 does not bind to human immunodeficiency virus
(HIV)(Baixeras et al., 1992).
1.2.2. LAG-3 expression pattern
A number of activated human T and NK cell lines, as well as PHA blasts of CD4 and
CD8 T cells express LAG-3 on their surface (Annunziato et al., 1997; Annunziato et al.,
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1996; Hannier and Triebel, 1999; Scala et al., 1998; Triebel et al., 1990). In
immunofluorescence studies, expression of human LAG-3 protein was reported mainly
on activated T cells in the inflamed secondary lymphoid organs, with a few scattered
positive cells in normal lymphoid organs. The morphology and distribution of LAG-3 +
cells were consistent with that of lymphocytes. No LAG3+ cell (Huard et al., 1994a) was
found in nonlymphoid organs including muscle, nerve and kidney. The distribution of
LAG-3, compared with CD3 and CD25, in normal human tissues is shown in Table 1.1.
   
Table 1.1. The distribution of LAG-3 in normal tissues, detected by staining of tissue
sections with mAb anti-human LAG-3 antibody. GC-germinal centers, Malt- mucosa-
associated lymphoid tissue,  - no positive cells, + a few positive cells, ++ many
positive cells, +++ most cells positive (Huard et al., 1994a).
Consistent with human studies, mouse antigen-activated T cells (CD4 and CD8
populations) as well as poly(I)-poly(C), the synthetic double-stranded ribonucleic
acid, activated NK cells express LAG-3 on their surface (Miyazaki et al., 1996;
Workman et al., 2002b).
Northern blot analysis of mouse tissues revealed LAG-3 transcripts only in the spleen,
thymus and brain and not in stomach, liver, lung, testis, heart, kidney and skeletal muscle.
Furthermore, a very small percentage of T and NK cells in naïve mice express surface
LAG-3, about 2% and 10 % respectively. Interestingly, in contrast to αβ  T cells,
significant percentage of γδ T cells (almost 19 %) show LAG-3 expression (Workman et
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al., 2002b). In addition, functional genomic screen of TCRγδ intraepithelial lymphocytes
revealed LAG-3 mRNA (Fahrer et al., 2001).
However, it must be mentioned that all the above in vivo T cell expression data is
reported in the form of tables and no primary results are shown (Huard et al., 1994a;
Workman et al., 2002b).
1.2.3. Regulation of Lag-3 expression
The studies concentrating on potential factors inducing LAG-3 expression on human T
and NK cells showed that certain cytokines: IL-2, IL-7, IL-12 up-regulated surface LAG-
3 expression, while others: IL-4, IL-6, IL-10, TNF-α , TNF-β and IFN-γ  did not
(Bruniquel et al., 1998). In fact, IL-12 proved to be the most potent stimulus for LAG-3
expression on activated T and NK cells (Annunziato et al., 1997; Bruniquel et al., 1998).
None of the above mentioned cytokines were able to down-regulate LAG-3 expression.
Aditionally, the most activated CD4+ T cell clones with established Th1 profile of
cytokine secretion expressed LAG-3 on their surface, whereas the great majority of Th2
clones showed neither surface LAG-3 nor LAG-3 m RNA expression (Annunziato et al.,
1996; Scala et al., 1998).
The analysis of the 5’ region of human Lag-3 gene revealed that LAG-3 has a TATA-less
promoter and, like many genes lacking a TATA box, it has multiple transcriptional start
sites. The LAG-3 transcription initiation sites are the putative Inr motives, as shown in
Figure 1.6a. Inr sequence is another transcriptional initiator DNA element (Javahery et
al., 1994). In addition, a number of regulatory regions upstream from the transcription
start site have been identified including the DNA binding motifs of GATA, c-Ets, NF-kB
and NFAT transcription factors and GC box, the putative binding site of Sp1 transcription
factor (Figure 1.6b) (Bruniquel et al., 1998). In particular, -1061/-541 region was
identified as positive regulatory element, while +211/+311 located in the first exon was
found to hamper the activity of regulatory elements upstream of the transcriptional start
site.
34
a)
 b)
Figure 1.6. The human LAG-3 5’ region. a) multiple Lag-3 transcription initiation sites
are compared with Inr sequence. b) The major transcription start site is marked as +1 and
the minor sites as (+1). The potential transcription factor binding sites are indicated.
Adapted from Bruniquel et al. 1998.
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1.2.4. Suggested function of LAG-3
The physiological role of LAG-3 is not clear. Since LAG-3, like CTLA-4, is expressed
only after lymphocyte activation, it cannot play a role in the induction phase of the
response. Because it has a higher affinity for MHC class II than CD4 (and therefore
potential for displacing CD4), however, it was thought that LAG-3 might act as a
negative regulator of T cell activation. Consistent with this prediction, addition of
blocking anti-LAG-3 antibodies to IL-2 dependent human T cell lines resulted in
sustained proliferation, increased CD25 activation marker expression and increased INF-
γ and IL-4 secretion (Huard et al., 1994b). Subsequent studies with polyclonal human T
cells showed that TCR-induced activation was inhibited by anti-LAG-3 Ab cross-linking
(Hannier et al., 1998).
It was also demonstrated that LAG-3 co-caps with CD3 at the immunological synapse,
but surprisingly it was preferentially associated with the CD8 rather than the CD4 co-
receptor at the cell surface (Hannier and Triebel, 1999). In addition, LAG-3 was found to
be enriched in lipid rafts of activated T cells (Iouzalen et al., 2001). Lipid rafts are
detergent insoluble, cholesterol and glycosphingolipids rich membrane microdomains,
which have been implicated in signal transduction, cholesterol trafficking and
endocytosis (Pike , 2004).
The initial analysis of LAG 3-/- mice did not reveal any defect in T nor B cell function
(Miyazaki et al., 1996). But two more recent studies showed that murine LAG-3 can act
as regulator of T cell expansion. These studies, however, showed different effects in vitro
than in vivo. In vitro, defective expansion of activated LAG3-/- T cells after
staphylococcal enterotoxin B (SEB) stimulation was observed. The effect was attributed
to the increased cell death, since the cells were proliferating at the normal rate (Workman
and Vignali, 2003). Similar observations were made with LAG3-/-CD4+ OT-II
transgenic T cells following antigenic peptide stimulation. Antigen-driven expansion was
restored by constitutive expression of LAG-3 via retroviral-mediated stem cell gene
transfer (Workman and Vignali, 2003). Yet, in vivo, LAG3-/- T cells exhibited a delay in
cell cycle arrest following stimulation with SEB resulting in increased T cell expansion
and splenomegaly. Moreover, increased T cell expansion was observed in adoptive
recipients of LAG-3 -/- OT-II transgenic T cells following in vivo Ag stimulation
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(Workman et al., 2004). Similarly, the infection of LAG3-/- mice with Sendai virus
resulted in increased numbers of memory and CD4+ and CD8+ cells (Workman et al.,
2004). This in vivo data supports the idea of LAG-3 being a negative regulator of T cell
activation and expansion.
The initial analysis of LAG3-/- deficient mice, nevertheless, showed a defect in the
natural killer cell compartment. Killing of certain tumor targets by NK cells from these
mice was inhibited or even abolished, whereas lysis of cells displaying MHC class I
disparities remained intact. It was thus suggested that LAG-3 is a receptor or co-receptor
defining different modes of NK killing (Miyazaki et al., 1996). This notion, however, was
not supported by studies with human NK cells (Huard et al., 1998).
Very recently, a new aspect of LAG-3 function was investigated. It was suggested that
surface LAG-3, besides modulating effector T cell activity, influences regulatory T cell
suppressor activity. Not only CD4+ CD25+ T cells from LAG3-/- mice exhibited reduced
regulatory activity, but also ectopic expression of LAG-3 on CD4+ T cells conferred on
them suppressor activity toward effector T cells (Huang et al., 2004).
LAG-3 expression is thought to be limited to activated T and NK cell populations, but it
has been shown to exert an effect on other cell types as well, particularly monocytes and
dendritic cells. For example, LAG-3 expressed on the surface of human proinflammatory
bystander T cells  (that is T cells in co-cultures with autologous monocytes and IL-2,
activated in the absence of TCR engagement) synergizes with low level of CD40 L
expressed on these cells to trigger TNF-α and IL-12 production by monocytes (Avice et
al., 1999). Furthermore, in the same way as soluble CD40 L, soluble LAG-3 can directly
induce DCs to produce Th1- cytokines and chemokines, known to direct the migration of
maturing DCs to lymph nodes (Andreae et al., 2002; Buisson and Triebel, 2003).
1.2.5. Mode of action of LAG-3
The mechanism of LAG-3 action has not been clarified. In some studies, it was
concluded the extracellular part is important, others suggested that the intracellular tail
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and thus the potential downstream signalling pathways play a role. For example, the
inhibitory effect of LAG-3 on CD4-dependent T cell function was lost upon deletion of
the LAG-3 cytoplasmic tail (Workman et al., 2002a), in accordance with the idea that
LAG-3 does not disrupt CD4 - MHC class II interactions but rather directly inhibits T
cell activation through intracellular signalling. LAG-3 could, therefore, be considered as
an independent (negative) co-receptor, like the other two TCR-assisting MHC ligands,
CD4 and CD8. The signal transduction pathways downstream of LAG-3, however, have
not yet been delineated. It is clear that the intracellular tail of LAG-3 does not contain
any immunoreceptor tyrosine-based inhibitory motif (ITIM) consensus sequences that are
usually found in various inhibitory receptors (Burshtyn et al., 1996; Vely and Vivier,
1997). But, three regions of putative importance are conserved in mouse and human
(Figure 1.4); EP (Glutamic acid - Proline) repeated motif is a binding site for LAP (LAG-
3 associated protein) a candidate molecule for a new type of signal transduction and/or
coupling of the immunological synapse to the microtubule networks (Iouzalen et al.,
2001; Triebel, 2003). KIEELE motif was reported to be important for the inhibition of
CD4-dependent, but not CD4-independent T cell function by LAG-3. While serine 454 is
a potential phosphorylation site for casein kinase II, cAMP and cGMP dependent protein
kinases (Workman et al., 2002a; Workman and Vignali, 2003). In contast to CD4, the
intacellular tail of LAG-3 contains no binding motif for Lck, a protein tyrosine kinase
crucial for early signal transduction events downstream of TCR.
Several alternate splice variants of human Lag-3 were described. Two of them encoding
potential truncated forms: LAG-3V1 (domains D1 to D2 of 36 kDa) and LAG3V3
(domains D1 to D3 of 52 kDa) suggesting the existence of soluble form of LAG-3
(sLAG-3) (Triebel, 2002). However, very recently it was shown that sLAG-3 isolated
from activated mouse T cell hybridoma cultures is a result of proteolytic processing
occurring at the connecting peptide region of surface LAG-3 rather than an alterative
splicing product. This soluble LAG-3 migrated at apparent molecular weight of 54 kDa.
In addition, the cross-linking experiments indicated that LAG-3 is present at the cells’
surface as a dimer and in oligomeric form (Li et al., 2004). Thus, it is possible that
soluble LAG-3 exists also as a multimer.
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The extracellular part of LAG-3 is thought to mediate its effect through binding to MHC
class II. It is conceivable that membrane bound LAG-3 and soluble LAG-3 (sLAG-3)
perform different functions in the immune system.
The longer form of LAG-3 was detected by ELISA in the serum of healthy individuals as
well as tuberculosis patients with favorable outcome (Lienhardt et al., 2002; Triebel,
2003). In fact, since LAG-expression correlates with IFN-γ production by activated T
cells, soluble LAG-3 has been even suggested as a serological marker of Th1 responses
(Annunziato et al., 1996). Soluble LAG-3 was also detectable by ELISA in the serum of
wild type mice (Li et al., 2004). The potential function of LAG-3 has been probed with
recombinant soluble LAG-3 composed of extracellular part of LAG-3 fused to human
IgG1 Fc region (mLAG-3Ig). Soluble mLAG-3Ig fusion protein induced MHC class II
mediated signaling in monocytes and dendritic cells leading to their activation and/or
maturation as well as production of cytokines (Andreae et al., 2003; Andreae et al., 2002;
Avice et al., 1999; Demeure et al., 2001). Moreover, sLAG-3 stimulated immature DCs
had a 4- to 5-fold increased capacity to stimulate naïve T cell proliferation (Demeure et
al., 2001). Consistently, co-administration of soluble mLAG-3Ig was shown to increase
CTL and CD4 Th1 responses in mice (El Mir and Triebel, 2000).
1.2.6. LAG-3 and cancer
LAG-3 has also been implied to have anti-tumor activity. For example, Lag-3 transfected
tumors completely regressed or their growth was markedly reduced in mice, and the
challenged mice were significantly protected against a re-challenge with parental tumor
cells. Likewise, the co-administration of soluble recombinant LAG-3 (mLAG-3Ig) with
wild-type tumor cells also reduced primary tumor growth (Prigent et al., 1999).
Another study, exploiting mammary tumor model in transgenic mice, found that co-
injection of soluble LAG-3 (mLAG-3Ig) enabled DNA vaccination with plasmids coding
for the oncogene product to establish effective protection against mammary
carcinogenesis. It elicited stronger and sustained (unlike DNA vaccination alone)
protection and kept 70% of 1-year old mice tumor free (Cappello et al., 2003).
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In human, T lymphocytes infiltrating various tumor types (melanoma, renal cell
carcinoma, diffuse large cell lymphoma, peripheral T cell lymphoma) were found to
express LAG-3 (Demeure et al., 2001).
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2. THESIS OBJECTIVES
Properly functioning immune system is essential for our health. Inadequate responses to
pathogens or tumors as well as hyper-reactivity leading to destructive autoimmune
disease have a direct impact on our survival. Hence, the immune responses have to be
under tight control. Especially, the regulation of T cells, the key players of adaptive
immunity, their activation and expansion, is crucial for the maintenance of the harmony
in the system.
Recently a novel cell surface molecule, called LAG-3 (Lymphocyte activation gene –3 /
CD223), was identified which has a potential regulatory role in the immune system. This
protein was detectable on activated T cells in human inflamed lymphoid tissues but not in
normal lymphoid organs. In vitro studies strongly suggested that LAG-3 plays a negative
role in T cell activation. However, the physiological role of LAG-3 remains unclear.
The goal of this thesis was to characterize mouse LAG-3. Mouse system allows for more
easily accessible and manipulable experimental approach needed to gain deeper insight
into the functional significance of this molecule. As there were no reagents available, the
first objective was to generate tools enabling the characterization of LAG-3 in the form of
(i) monoclonal antibodies against LAG-3, (ii) the recombinant soluble LAG-3, as well as
(iii) LAG-3 transduced cell lines. There was only scarce information about murine
LAG-3 expression pattern, this surface glycoprotein was found only in activated T and
NK cells. Monoclonal antibodies would offer the possibility to undertake detailed
analysis of LAG-3 expression pattern and function in the immune system. It would also
allow for studying how different activation regimes of purified immune cell populations
or their mixtures induce LAG-3 expression. Recombinant soluble LAG-3, on the other
hand, would open the possibility to undertake structural investigations of the protein.
Therefore, another goal was to find and optimize the conditions for a large-scale
production of soluble recombinant LAG-3, in Drosophila cells expression system. The
purified soluble LAG-3 would be subjected to crystallization trials alone or in complex
with its reported ligand - MHC class II. If successful, the detailed structural information
may help understanding how LAG-3 interacts with its ligand. LAG-transduced cell lines
could give us indications about the biological role of LAG-3.
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The last objective was to use LAG-3 deficient mice to confirm the specificity of our
reagents and to verify our in vitro observations.
All these approaches were aimed at gaining a deeper understanding of LAG-3 function in
the immune system.
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3. MATERIALS AND METHODS
3.1. Materials
3.1.1. Plastic ware
Flasks, plates, pipettes, roller bottles, conical tubes Costar/Falcon,
Freezing vials Nunc Inc.
Microfuge tubes/ PCR tubes Eppendorf
Filter bottles Millipore/Corning
Immulon 2 plates Dynex
FACS tubes Micronic
3.1.2. Chemicals and additives
Agarose (ultra pure) Gibco BRL
Aluminium Potassium Sulfate (APS) Sigma
Ammonium Persulfate (APS) Amresco
Ammonium sulfate Fluka
Ampicillin Sigma
ABTS(2,2’-Azino-bis(3-ethylbenzothiazoline
-6-sulfonic acid) diammonium salt Sigma
β-mercaptoethanol Sigma
Bacto agar Difco
Bacto-tryptone Difco
Bacto-yeast extract Difco
Bovine Serum Albumin (BSA) Sigma/Biolabs
Ciproxin (0.2 g in 100ml solution) Bayer
CFSE (carboxyfluorescein diacetate, succinimidyl ester) Molecular Probes
Copper sulfate (CuSO4) Fluka
Dextran sulfate (sodium salt) Pharmacia
DEPC (diethyl pyrocarbonate) Sigma
Dithiothreitol (DTT) Sigma
DMSO(dimethyl sulfoxide) Fluka
EDTA (ethylenediaminetetraacetic acid) Fluka
Ethanol Merck
Ethidium bromide Merck
FCS (Fetal Calf Serum) Seromed
Glycerol Sigma
Glycine Fluka
HeaIII/HindIII DNA size marker New England Biolabs (NEB)
HAP Bio-Rad
HAT(50x) Boehringer/Roche
HCL Merck
HEPES Sigma
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H2O2 Fluka
HT (50x) Boehringer/Roche
Hygromycin Calbiochem
IMDM powder stock Gibco
Insulin Sigma
Isopropanol Merck
Leupeptin Sigma
LPS (lipopolysaccharide) Sigma
MEM non essential amino acids 100x solution Gibco BRL
Methanol Merck
Milk (powder, blotting grade) Bio Rad
NaOH (10M) Fluka
Nonidet P-40 (NP-40) Fluka
Pepstatin A Sigma
Paraformaldehyde (PFA) Sigma
PEG (polyethylene glycol) 1500 Boehringer
Penicillin /Streptomycin 100x solution Gibco BRL
PMSF (phenylmethylsulfonyl fluoride) Sigma
PRIMATONE ® RL/LF Quest International
Puromycin Calbiochem
Sodium azide Fluka
Sodium dodecyl sulfate (SDS) Bio Rad
Sodium carbonate (NaHCO3) Fluka
TEMED (N,N,N',N' - tetramethylethylene diamine) Amresco
Tris Merck
TNF-α Pharmingen
Triton X-100 Bio Rad
Tunicamycin Sigma
Molecular biology enzymes were purchased from BioLabs, Roche or Gibco BRL.
3.1.3. Media and Buffers
IMDM medium IMDM powder for 10l
30.24 g NaHCO3
up to 10 l Millipore H20
Serum free-medium:( SF-IMDM) IMDM containing:
50µM β-mercaptoethanol
50 units/ml Penicillin
50 µg/ml Streptomycin
1 x non-essential amino acids
5 µg/ml Insulin
0.03 % Primatone RL
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LB medium:         10g Bacto-tryptone
5g Bacto-yeast extract
10g NaCl
H2O up to 1l
LB agar: LB medium 1l
15g Bacto agar
SOB-Mg            10g Bacto-yeast extract
0.5g NaCl
10ml 250mM KCl
H2O add 1l
SOB – Mg agar plates SOB- Mg medium 1l
15g Bacto agar
EWB 10% redistilled glycerol in ultrapure water
TE 10mM Tris-HCl (pH 8.0)
 1mM EDTA
Phosphate buffered saline (PBS): 80g NaCl
28.8g Na2HPO4x12H20
2g KCl
2g KH2PO4
add up to 10l H20 bidestilled
1xGey's solution: 20 parts stock A
  5 parts stock B
  5 parts stock C
70 parts cell culture grade H20
Stock A: NH4Cl 35.0g
KCl 1.85g
Na2HPO4.2H2O 1.5g
(or Na2HPO4.12H2O 0.75g)
KH2PO4 0.12g
Glucose 5.0g
Phenol red      50.0mg
in 1000ml H20
Stock B: MgCl2.6H2O 0.42g
MgSO4.7H2O 0.14g
CaCl2 0.34g
(or CaCl2.2H2O 0.45g)
in 100 ml H20)
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Stock C: NaHCO3 2.25g
in 100ml H20
Rnase-free water DEPC-treated water
SF-900 II SFM  Gibco
DMEM Gibco
HBSS without Ca2+ and Mg2+ Sigma
TAE 40mM Tris/acetate, pH 8
1mM EDTA
Tris-glycine electrophoresis buffer 25mM Tris
250 mM Glycine (pH 8.3)
0.1% SDS
SDS-PAGE  sample buffer 4x 200 mM Tris-CL (pH 6.8)
8% SDS
0.4% bromophenol blue
40% glycerol
Glycine - HCL buffer pH 3.2 50ml of 0.2M glycine
8.2ml of 0.2M HCL
141.8 ml H20
Glycine - HCL buffer pH 2.8 50ml of 0.2M glycine
16.8ml of 0.2M HCL
133.2 ml H20
ABTS substrate solution for 20 ml
18ml Mc Ilvain’s buffer
2 ml ABTS (10mg/mL)
1% H2O2
OptiprepTM dilution buffer 0.88% NaCL
1mM EDTA
10mM Hepes-NaCl
0.5 % BSA
pH 7.4
filter sterilized 0.2 µm
IL-2, IL-4, Il-6                                                X63 cell line carrying expression vector for
a given cytokine
(Karasuyama and Melchers, 1988)
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3.1.4. Special Reagents
CpG 1826 Microsynth, Balgach, Switzerland
OVA 323-339 peptide Seccion de Proteomica, Universitat
Pompeu Fabra, Barcelona, Spain
HA 110-119 peptide Basel Institute for Immunology
peptide facility, Basel
dNTPs Amersham Pharmacia
T4 ligase Roche
Reverse transcriptase Roche
Ficoll-PaqueTM Pharmacia
OptiprepTM Nycomed
DMRIE-C Reagent ® Gibco BRL
Lipofectin® Gibco BRL
Lipofectamine ® Gibco BRL
GELCODE® Blue Stain Reagent Pierce
BENCHMARKTM protein size marker Invitrogen
Collagenase D Boehringer Manheim
TRIzol Gibco
Hyflo Super Cell ® Fluka
Fluorescently labelled antibodies were purchased from BD Pharmingen.
Unlabeled antibodies were produced and purified from respective hybridomas. When needed
purified Abs were biotinylated.
Rabbit polyclonal anti-mouse LAG-3 Ab was produced in our lab by
Giuseppina Sollami
Goat anti-rabbit horseradish peroxidase
HRP) liked Ab Southern Biotechnology Associates,
Inc.
Goat anti-rat Ig HRP linked conjugate Tagoimmunologicals
Goat anti-rat IgG-biotinylated Pharmingen
Goat anti-rat IgG2a-biotinylated Pharmingen
Goat anti-rat IgG2b-biotinylated Pharmingen
Streptavidin - Texas Red Molecular Probes
3.1.5. Other materials
Electropration cuvette Bio Rad
MACS LS Separation columns Miltenyi Biotec
Streptavidin MicroBeads Miltenyi Biotec
PD-10 Columns Amersham
CNBr activated Sepharose Pharmacia
G+ Sepharose Pharmacia
Poly-D lysine Sigma
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Nylon Net (Nitex) Nytal
Microscpe Slides, SuperFrost Plus Menzel-Glaser
Cover Slips, D=15 “Assistant” Ominilab
3.1.6. Kits
Geneclean TM Bio 101
Plasmid mini-prep GenecleanTM RPM Bio 101
Plasmid maxi-prep QIAGEN
DNA Ligation Kit Roche
Gel purification kit GenecleanTM Bio 101
BigDye® Terminator Cycle Sequencing Kit Applied Biosystems
ECL Kit Pharmacia
3.2. Methods
3.2.1 Molecular biology techniques
-  preparation of electro-competent bacteria
Bacteria used for transformations were prepared in the following way: single colony of
E.coli (strain DH10B or XL-Blue) was picked form freshly streaked agar plate and
resuspended in 1mL of SOB-Mg medium by vortexing. The cells were used to seed 50
mL of SOB-Mg medium and grown overnight at 37°C and 275 rpm. The following day
7.5 mL of this fresh culture were used to inoculate 750 ml of SOB- Mg medium. The
bacteria were incubated at 37°C with moderate agitation until optical density of 0.75
units at 550nm was reached (corresponding to 3-6 x 108 cells per ml). Then cells were
collected by centrifugation at 2600g for 15 min. at 4°C. The bacteria were resuspended in
750 ml of EWB, centrifuged, and the wash step was repeated. The pellet was resuspended
in the few drops of liquid left in the centrifugation tube. Volume was then adjusted with
EWB to obtain OD 550 >200 units and frozen in 50 µl aliquots and stored at –70°C.
- transformation of bacteria
An aliquot of electro-competent bacteria was thawed on ice, 1 µl of DNA solution
(plasmid preparation or ligation mix, ethanol and detergent free) in 0.5 TE was added.
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The cells were kept 1 min on ice, transferred to pre-chilled electoporation cuvette and
electroshocked (12.5 kVper cm, 25 µF, 200 Ohms). Immediately after shock, 1 mL LB
medium was added to the cuvette and the cells were transferred into an Eppendorf tube
and incubated at 37°C for 1hr, with shaking. The bacteria were plated on agar plates
containing the selection antibiotic ampicillin (50 µg/ml) and incubated o/n at 37°C.
- ligation of DNA fragments  into a plasmid vector
Ligations were performed in total of 10 µl volume using 1 Weiss units of T4 ligase in the
buffer supplied with ligase by the manufacturer for 1hr at room temperature. 1:3 vector to
insert ratio was used. Vectors and inserts digested with appropriate restriction enzymes
were purified using Geneclean TM purification kit.
- restriction digests and analysis of plasmid DNA
In order to analyse plasmid DNA or prepare fragments for ligation, the DNA was
digested with the appropriate restriction enzyme in the buffer supplied with the enzyme.
The cut DNA was analyzed on 0.8 to 2% (depending on the size of the fragment) agarose
gel containing ethidium bromide (allowing visualization of DNA under UV light). The
gels were run in TAE buffer at 80 V.
- small and large scale plasmid preparation
For small-scale plasmid preparation a single bacterial colony was transferred into 2 mL
of LB medium (ampicilin 50 µg/ml) and grown o/n at 37°C with vigorous shaking. 1.5ml
of the culture was transferred to a microfuge tube and cells were harvested by
centrifugation.  The Geneclean TM RPM Kit was used according to the supplied protocol.
For large plasmid DNA preparation bacteria from 100 ml overnight culture (seeded with
2 mL of small scale culture) were harvested by centrifugation at 6000 g at 4°C for 15 min
and the QIAGEN® maxi plasmid purification protocol was followed using supplied
reagents.
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- DNA sequencing
For sequencing of DNA constructs, 2 µl of plasmid DNA (200-500 ng) was mixed with 2
µl of appropriate primer (10 µM), 8µl of H20 and 8µl of BigDye sequencing mix
(Applied Biosystems). The reaction was subjected to 25 extension cycles (96°C 30 sec.,
50°C 15 sec., 60°C 2 min.) and followed by isopropanol precipitation (2 µl of 3M NaAc
and 20µl of isopropanol). The pellet was dissolved in 18 µl of TCR (template suppressor
reagent, BigDye® Terminator Cycle Sequencing Kit), heated up to 95 °C for 5 min. and
run on Genetic Analyzer 310 (Applied Biosystems).
- RNA purification
RNA was purified using the TRIazol reagent. Cells were lysed by pipetting up and down
in the appropriate amount of TRIazol reagent (1ml per 5-10x106 cells). The mixture was
additionally incubated for 5 min. at RT, then 0.2 ml of chloroform was added per 1 ml of
TRIazol used at the beginning, the tube was shaken vigorously by hand for 15 seconds
and incubated for 3 min. at RT. Following centrifugation at 12000x g for 15min. at 4°C,
the upper (aqueous) phase was transferred to a fresh tube and RNA was precipitated by
the addition of 0.5 ml of isopropanol per 1ml TRIazol used for cell lysis. After another
centrifugation and washing with 70% ethanol, RNA was dissolved in RNase-free water,
and the A260 was measured to determine the yield.
- RT-PCR reverse transcription - polymerase chain reaction
For the first strand synthesis the RNA was dissolved in 10µl RNase-free water, 500ng of
the cDNA synthesis oligonucleotides (random hexamers) was added and the mixture was
heated for 15min. at 65oC. Then the following components were added:
6.6µl 5x reverse transcriptase buffer
1 µl 0.1M DTT
3.3µl 10mM dNTP’s
1.3µl BSA 2.5mg/ml
1µl human placental RNase inhibitor
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1.5 µl Superscript RNase H-MMLV reverse transcriptase
RNase-free water up to 33 µl was added.
In that volume up to 5µg mRNA can be reverse transcribed.
The obtained cDNA was used as a template for PCR. PCR is a technique that allows the
amplification of a given DNA fragment that is flanked by short known sequences. The
DNA from which the DNA fragment has to be amplified, is mixed with large excess of
single-stranded oligonucleotides that are complementary to the flanking sequences, Taq
polymerase, dNTP’s and the buffer. One oligonucleotide is complementary to the
antisense of the 5'-flanking sequence, the other to the sense of the 3'-flanking sequence
and they are typically 20 bp long. When the mixture is heated the DNA gets denatured,
then the oligonucleotides can anneal to the DNA and the Taq polymerase can amplify the
appropriate fragment. The program used for LAG-3 amplification from cDNA was: 
Step 1:  2’ 95°C
Step 2:  20” 95°C
Step 3:  10” 55°C,
Step 4:  90” 72°C
Step 5:  step 2 to 4  - 29 times
Step 6:  10’ 72°C
The products of the reaction were visualized on a 1.5% agarose gel.
- preparation of expression construct for production of soluble LAG-3
The coding sequences for D4t (nucleotides 357-1769) and D2t (nucleotides 357-1122) of
Lag-3 were amplified from thymus cDNA by PCR using primers with EcoRI restriction site
overhang (forward primer) and BglII restriction site overhang (reverse primer) and cloned
into pRmHa-3 vector multiple cloning site by standard molecular techniques. The result is
shown in Figure 3.2.1. The mini-preparations of the potential plasmid clones were sequenced
to make sure that no mutations were introduced during PCR reactions. Subsequently maxi-
preparations of pRmHaLAG-3D4t and pRmHaLAG-3D2t were done.
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Figure 3.2.1 The DNA constructs for LAG-3 truncations: D4t (domains D1 to D4) or D2t
(domains D1 to D2) were cloned into pRmHa-3 Drosophila expression vector, under the
control of Drosophila metallothonein (MT) promoter and in front of Drosophila alcohol
dehydrogenase polyadenylation signal (Bunch et al., 1988).
3.2.2. Biochemical techniques
- purification of monoclonal Abs
A monoclonal antibody-producing hybridoma cell line was grown in 2% FCS SF-IMDM
in roller bottles until 20-30% of cells were dead. The culture supernatant was filtered
over Hyflo Super Cell ® on 0.45um filter to remove cells and prevent the clogging of the
subsequently used affinity column. Sodium azide (0.05% final) was added to the
supernatant and the supernatant was run twice through protein G+ Sepharose column at
4oC. After washing with 10-20 column volumes of PBS the antibody was eluted in 3ml
fractions with HCL-glycine buffer of pH 2.8. Elution was monitored by UV absorption at
λ =280 (A280). Immediately after collection, pH of each fraction was adjusted to 7 with
~2M Na2PO4. The antibody concentration was determined by measuring A280 (OD 280
of 1 corresponding to approximately 0.75 mg/ml of purified Ab). The Abs were stored at
4°C for short-term and at –20°C for long-term storage.
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- labelling of antibodies with biotin
Purified antibodies were dialysed against 0.1 M NaHCO3 (pH 8.2-8.6) in order to remove
glycine. Glycine needs to be removed because it inhibits biotinylation reaction.  To 1
mg/ml of antibody, 40µl of biotin succinimidyl ester stock solution (10 mg/ml in DMSO)
was added for every ml of antibody. After incubation for 1h at RT unbound biotin was
removed by gel filtration on PD-10 columns. The biotinylated antibodies were stored at
4°C for short-term use or aliquoted and stored at –70oC.
- preparation of affinity columns
1g CNBr activated Sepharose was suspended and washed in low pH (1mM HCl in
water), resuspended in PBS containing 3mg of a purified monoclonal antibody per 1 ml
of Sepharose and incubated over night at 4°C under head-to-tail rotation. The ligand was
removed and the remaining amine groups were blocked in 125mM Tris-HCl 1M glycine
(pH 8) for several hours. The beads were then washed with PBS and column was set up.
The column was primed with elution buffer, neutralized with PBS before use.
- enzyme linked immunosorbent assay (ELISA), sandwich ELISA
ELISA-microtiter plates Immulon2 (Dynex) were coated o/n at 4oC with 1-10 µg/ml
protein in PBS. The plates were thoroughly washed with PBS and blocked for 1h at 37oC
with 4%BSA in PBS. After washing with PBS, the desired antibody, protein or cell
culture supernatant was applied for 1h at RT. The plates were then washed 3 times with
PBS and secondary HRP linked antibody (anti-rat) or HRP linked straptavidin were
added for 30 min. After washing (3 times with PBS) the ABST substrate solution was
added (100µl/well) and incubated at RT for 20-30 min. ABTS produces a green coloured
product upon reaction with HPR, which can be measured photospectrometrically at
405nm.
For sandwich ELISA experiments the plates were coated with purified monoclonal anti-
LAG-3 Abs at 2µg/ml.
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For isotyping of monoclonal antibodies, the plates were coated with soluble LAG-3D4t
(2µg/ml in PBS), and anti-rat IgG2a or anti –rat IgG2b (Pharmingen) were used as
secondary reagent, followed by Streptavidin –HRP.
-SDS-PAGE
Polyacrylamide separating gel was prepared according to the following protocol:
S e p a r a t i n g  g e l
percentage 12% 10% 7.5%
 stacking gel (5.0%)
Deionized water 4.35ml 4.9ml 5.6ml 2.87
1.5M Tris-HCl,pH8.8
1 M Tris-HCl,pH6.8
2.5ml 2.5ml 2.5ml
0.5ml
10%(w/v) SDS 100µl 100µl 100µl 40µl
40% Acryl./Bisacryl 3.0ml 2.5ml 1.75ml 0.5ml
10% APS 100µl 100µl 100µl 40µl
TEMED 4µl 4µl 6µl 4µl
Total 10ml 10ml 10ml 4ml
Separating gel was poured and left to polymerize for one approx. 1 hour at RT. Then the
stacking gel was prepared. Samples were loaded on a gel in 1x loading buffer. For
reducing conditions DTT at final concentration of 100 mM was added to the samples.
The samples were subjected to electrophoresis in Tris-Glycine buffer at 200V for 45min-
1 hr along with BENCHMARKTMsize marker in the Bio-rad minigel apparatus.
- analysis of polyacrylamide gels with GELCODE® Blue Stain Reagent
The polyacrylamide gels were washed 3 times for 5 minutes with deionized water, then
immersed in GelCode® Blue stain reagent, and incubated at RT for 1 hr gently rocking.
After staining the gel was washed in water at RT for 1 hr, the gels were scanned to save
the image.
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- preparation of the total protein lysates from cells
Cells were lysed in the lysis buffer at the concentration of 107-108cells per ml of lysis
buffer by repeated pipetting and 30 min. incubation on ice. Then the insoluble fraction
was spun down ( 20 000 xg, 10 min, at  4oC ) and the supernatant was collected.
Lysis buffer included: 1% NP-40, 50 mM Tris pH 7.8, 150mM NaCl, 1mM EDTA and
Complete® protease inhibitors cocktail.
- Western blot analysis
After protein samples were separated on an SDS-polyacrylamide gel, the electrophoretic
transfer to the membrane was done in the Tris-glycine transfer buffer containing 20%
methanol for 1 hr at 350mA. After blocking for 1 hr with 4% non-fat milk in PBS at RT,
the membrane was incubated with the first step antibody (polyclonal rabbit anti-LAG-3)
for 1h at RT and washed in the same buffer for 15 min. The secondary antibody (goat
anti-rabbit labelled with horse radish peroxidase (HRP)) was added for 45 min. at RT and
after washing 3 times for 10 min. with PBS the blot was developed with the ECL Kit.
The chemiluminescence was recorded using LAS-1000 Imaging System (Fujifilm).
- saturated ammonium sulfate (SAS) precipitation
Splenocyte culture supernatants were centrifuged 30 min at 20 000xg at RT and
transferred to a fresh tube. Saturated ammonium sulfate (SAS) was added slowly with
stirring up to 45% (v/v). Precipitation was carried out at 4 C for 2 hrs. Samples were
centrifuged again 30 min at 20 000 x g at RT. Precipitates were dissolved in PBS and
used immediately or stored at –20°C.
- production and purification of soluble LAG-3
After a 3-week selection period, the expression of recombinant proteins was induced in
stably transfected SL-3 cells (see below) by adding CuSO4 to a final concentration of
1mM. Three days later (longer induction times are not recommended, since prolonged Cu
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treatment leads to a decrease in cell number (Bernard et al., 1994)), cell lysates and
supernatants were tested for the presence of soluble LAG-3 with SDS-PAGE and
immunoblotting.
For large-scale cultures roller-bottles were used (450-500ml culture per roller bottle).
LAG-3D4t cultures reading the cell density of 5x 106 /ml were induced with CuSO4 for 2-
3 days and the supernatant was harvested by centrifugation (10 min at 2100g, 4°C)
followed by 0.45 µm membrane filtration. At this point protease inhibitors (from 500x
stock) were added to the supernatant to prevent degradation of soluble protein. Inhibitors
stock solutions were: EDTA 500 mM, Leupeptin 0.250 mg/ml, Pepstatin 0.350 mg/ml,
phenylmethylsulfonyl fluoride (PMSF) 50 mg/ml. The supernatant (now also containing
sodium azide (0.05%) to prevent bacterial contamination) was then loaded on an anti-
LAG-3 antibody column (monoclonal Ab G40) at 1-2 liters per day flow rate. The
affinity column was extensively washed with PBS. Bound material was eluted with
Glycine-HCL buffer of pH 3.2. Fractions were immediately neutralized with Na2PO4
(app. 2M ) to bring pH up to 7.0, and stored at 4°C.
For production of de-glycosylated LAG-3D4t, tunicamycin (from Streptomyces sp.
T7765, Sigma), at final concentration of 1µg/ml was added to the cultures at the point of
induction.  Tunicamycin was diluted from stock cultures prepared by dissolving 5 mg/ml
tunicamycin in alkaline water (pH 11) and stored at -20 °C in 0.25 ml aliquots.
Purification of the de-glycosylated protein was carried out as for glycosylated LAG-3D4t.
-immunocytochemistry
First, the poly-D-lysine glass slides were prepared in the following way: cover slips were
washed with ethanol, dried and flooded with poly-D-lysine (0.1 mg/ml in PBS from
10mg/ml stocked prepared in water) for 30 min at RT. The excess of poly-D lysine was
removed by aspiration, the slips were rinsed with cell culture grade H20 and dried.
Everything was done under sterile conditions.
A5 or A5LAG-3 cells were grown on poly-D lysine coated glass slides to 60-80%
confluency. The cells were fixed in 1.8% paraformaldehyde 10 min at RT washed with
PBS and blocked with 2% BSA 10% FCS PBS for 10-20min at RT. Incubation with the
primary reagent; biotinylated Abs in blocking buffer was carried out for 1hr (RT). The
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cells were washed with PBS and streptavidin Texas Red was used as secondary reagent
(1hr at RT). After PBS wash, the slips were placed on microscope slides and viewed
under fluorescent microscope (Nikon).
3.2.3. Cellular biology techniques
- cell culture
For cell culture work all the media and reagents were filtered through 0.2µm Millipore
filters before use. Lymphocytes isolated from spleens and lymph nodes of mice and
mouse cell lines were cultured in SF-IMDM supplemented with 2% FCS, in this work
referred to as normal growth medium, in 95% humidity, 5% CO2 and 37oC.
For culturing of A5 cells hygromycin at 300 µg/ml was added to the growth medium.
For culturing of LAG-3 transfected cell lines puromycin at 2.5 µg/ml was added to the
growth medium.
For culturing of sorted cells Ciproxin was added (at final concentration 10 µg/mL) to the
normal growth medium to prevent contamination.
For freezing of mouse cells 40% FCS 10% DMSO normal growth medium was used.
- transfection of cell lines
A5 (HA specific CD4 T cell hybridoma) cell line was transfected using DMRIE-C
Reagent ® according to manufacturer’s instructions.
- transduction of  A20 cells
GP-E 86 packaging cell line (Markowitz et al., 1988) (provided by prof. Antonius Rolink,
University of Basel) was stably transfected with pLXS-puro vector (Backstrom et al.,
1996) carrying murine Lag-3 in the following way: 1.6 x 106 cells were plated in 75 cm2
flask a day be fore to reach 80% confluency on the day of transfection.  12 µg of plasmid
DNA were diluted in 600 µl of serum free medium (DMEM) and separately 36 µl of
Lipofectamine® Reagent were diluted in 600 µl of serum free DMEM, the two solutions
were combined and incubated at RT for 30 min. Cells were washed with serum free
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medium. 4.8 ml of serum free DMEM were added to the tube containing lipid-DNA
complexes and the mixture was overlayed onto washed cells, followed by 5 hrs
incubations at 37 °C. Then 6 ml of 20% FCS DMEM was added to the cells (without
removing transfection mixture). Next day the medium was replaced by normal growth
medium and the puromycin selection (2.5 µg/ml) was started day after.
Stably transfected GP-E86 cells were grown to 60-80% confluency (without puromycin)
and irradiated (3000 rads), the growth medium was changed and A20 cells were co-
culture with irradiated GP-E86 cells for 2-3 days, followed by transfer to a new flask and
puromycin selection in the normal growth medium.
- cell culture and transfection of Drosphila melanogaster cells
Schneider cells (SL-3) were grown in the Sf- 900 II SFM supplemented with 1% FCS at
densities between 5x105 per mL and 2x106 per mL at room temperature. SL-3 cells were
transfected with 1.5 µg of pRmHa-3LAG-3D4t or pRmHa-3LAG-3D2t together with 0.1
µg of phshspuro-2 DNA plasmid (containing the puromycin resistance gene under the
control of heat shock promoter (Steller and Pirrotta, 1986)) using Lipofectin® reagent
according to the manufacturer’s protocol. Transfections were performed in 24-well plate
and puromycin selection (5µg/ml) was started two days later. Puromycin was chosen as a
selection marker, rather than commonly used hygromycin B or geneticin, because it
reduces the time required for selection to 2 weeks (compared to 3-4 weeks for
hygromycin B and 5-6 weeks for geneticin (Towers and Sattelle, 2002)).
Colonies of drug-resistant cells could be seen about 1 week later.  Cells were expanded
and kept in culture or frozen in SF-900 II SFM containing 30% FCS and 10% DMSO.
- generation of B cell hybridomas by cell fusion
Lymph node single cell suspension taken from an immunized rat and the SP2/0 myeloma
cell line were washed with pure IMDM and spun down together in one tube. 1-2 large
flasks of SP2/0 cells in logarithmic growth phase per lymph node were used per fusion.
1.0 ml PEG1500 was added to cells within 1 min. while shaking in a 37oC water bath.
After another 90 seconds of shaking, the suspension was diluted with 5ml IMDM drop-
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wise over the course of 90 seconds. All was done in 37oC water-bath in 50ml Falcon
tube. The tube was finally filled up with IMDM and after centrifugation, the cells were
resuspended in 1 liter of HAT, IL-6, and 2%FCS SF-IMDM medium and plated out in 96
well plates (200 µl/well).
- preparation of cell suspension from mouse lymphoid organs
Freshly isolated spleen(s) and/or lymph nodes were transferred on a nylon net (Nitex) in
petri dish with PBS 2% FCS. The cell suspension was made by gently pushing the organs
though the net. The cell suspension was transferred into a 15mL Falcon tube and pelleted
by centrifugation at 300g for 5-10 min. If the cells were used for biological assay, the
procedure was done under sterile conditions.
- lysis of erythrocytes
Splenocytes were collected by centrifugation (10 min, 300g) and resuspended in normal
growth medium (1 ml of per 1 mouse spleen).  4 ml of Gey’s solution was added per 1ml
of cell suspension, the mix was incubated at room temperature for 1 min., after which 5
ml (per 1 ml of original cell suspension) of normal growth medium was added to the
tube. This treatment is based on hypotonic shock to which erythrocytes are very sensitive.
- preparation of dendritic cells from lymphoid organs
The total spleen or LN cell populations of wild-type mice (Balb/c strain) were enriched
for dendritic cells by density centrifugation using Opti-prep® reagent.
Peripheral lymph nodes (inguinal, popliteal, axillar and auricular) and spleens of Balb/c
mice were collected. Tissues were cut into small pieces and digested twice for 30 min. at
37°C in IMDM supplemented with 5% FCS and 100µg/ml collagenase D (37 °C room,
gentle shaking). Cells were recovered, passed through a mesh (to get single cell
suspension), centrifuged (5 min., 300g 4°C) and resuspended in HBSS (modified HBSS
without Calcium and Magnesium) supplied with 25mM Hepes and 5mM EDTA (6 ml for
4-5 spleens). 3 ml of cell suspension was mixed well with 1 ml of OptiprepTM reagent
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and placed in a 14 ml Falcon polycarbonate tube, 5 ml of 1 to 4.2 dilution of OptiprepTM
(1 unit Optiprep to 4.2 units Optiprep dilution buffer) was then layered over cell
suspension followed by 3 ml of HBSS. The gradient was centrifuged at 600g for 15 min.
at RT without a brake. The layer between HBSS and OptiprepTM dilution  (DC-enriched
phase) was collected and washed with 5% FCS IMDM. The enrichment varied between
30 to 60 fold. The obtained cells were cultured or stained with antibodies for flow
cytometric analysis and/or cell sorting.
 - surface staining of cells for FACS analysis and purification
Staining of cells was performed in 96-well V-bottom plates. For all stainings involving B
cells, the cells were incubated with anti-mouse CD16/CD32 (2.4G2) antibody at 10µg/ml
for 5-10 min on ice to block Fc receptors. 105-106 cells per well were stained with the
given antibody at the pre-determined dilution (usually 10-20µg/ml was optimal) in
2%FCS PBS on ice for 5-15 min. MAbs were used alone or in various combinations.
They were either directly labelled with Fluorescein Isothiocyanate (FITC), R-
Phycoerythrin (PE), Peridinin Chlorophyll (PerCP) or Allophycocyanin (APC)- or were
biotinylated. The latter ones had to be revealed by secondary staining with Streptavidin
–PE or FITC. After each incubation cells were washed once with 2%FCS PBS. Until
analysis was undertaken, samples were kept on ice. Analysis was done on a FACScalibur
flow cytometer (Becton Dickinson).
If cells were to be sorted and cultured, all procedures were done under sterile conditions.
For larger cell numbers (106-108) 14 ml Falcon tubes were used. Cells were suspended at
a concentration of 5x106 per ml for FACS and 30x106 per ml for cell sorting, and filtered
through a nylon mesh.  Cell sorting was performed on FACSAria (Becton Dickinson).
- MACS purification/enrichment of cells
MACS (Magnetic Cell Sorting) LS Separation Columns were used for enrichment and/or
purification of T cells or B cells according to the manufacturer’s instructions (Miltenyi
Biotec). Biotinylated primary antibodies (CD4 or CD19, respectively) were used for
labelling, followed by Streptavidin MicroBeads.
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- CFSE labelling
CFSE was dissolved in DMSO to 5mM (stock solution), aliquoted (10 µl per tube) to
avoid repeated freezing and thawing which may degrade the reagent and stored at- 20°C.
For labelling, cells were resuspended in 0.1 % BSA/PBS at 107 cells/mL and CFSE at a
final concentration of 5µM was added to them. The cells were then incubated at 37°C
(water bath) for 10 min. The reaction was stopped by adding 10-20 x volume of 0.1 %
BSA/PBS. The cells were centrifuged for 10 min at 300g, washed once with the growth
medium (room temperature) and used right away for culture.
- stimulation of T cells
Total splenocytes, sorted T cells or A5 cells were stimulated with anti-CD3 Ab
(145.2C11) alone or in combination with anti-CD28 Ab (37.51). The 24 or 96 flat bottom
plates were coated with the antibodies at 2µg/ml in PBS for 2-3 hours at room
temperature or overnight at 4°C, and washed once with PBS before plating cells.  Cells
were plated at 2x106 per well (24 well plates) or 0.2 - 0.3 x106 per well (96 well plates).
For antigen specific stimulations A20 B cell lymphoma was used as antigen presenting
cells. After γ-irradiation (30Gy) A20 cells were washed once with the growth medium
and loaded with various concentrations of HA peptide (SSFERFEIFPK) for 2hrs at 37°C.
- stimulation of B cells
Purified B cells were plated 0.1 mln cells/well (96 well flat bottom plates) in normal
growth medium supplied with 2%FCS. For stimulations CpG 1826 (Ballas et al., 2001) at
final conc. 0.3  µg/ml ,  LPS at final conc. 25  µg/ml ,  purified anti-mouse CD40 mAb
(FGK-45) and  anti-mouse Ig κ L chain mAb (187.1) (10 µg/ ml each Ab) supplemented
with IL-4, were used.
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- stimulation of dendritic cells
The cell population enriched for dendritic cells or sorted dendritic cells were plated in
round bottom 96 well plates, 1 x105 cells/well (spleen DCs) or 1-2 x104 cells/well (LN
DCs). Final concentrations of stimuli were: LPS -25 µg/ml, anti-CD40 antibody (FGK-
45) -10µg/ml, TNF- 50 ng/ml, CpG 1826 - 0.3 µg/ml.
- regulatory cell assay
Sorted CD4+ CD25- CFSE labelled effector T cells (2.5 x104), 1 x 105 irradiated (20 Gy)
WT splenocytes, and sorted CD4+CD25+ regulatory T cells (2.5 x104) or non-labelled
effector cells (2.5 x104) were plated in round bottom 96 well plates in the normal growth
medium. Cultures were stimulated with various doses of soluble anti-CD3 Ab (145.2C11)
for 4 days. Effector T cells activation was determined by CFSE dilution analysis.
- removal of dead cells with Ficoll-Paque
Cells were resuspended in normal growth medium at 1-5 x108 cells/ml and 5ml of Ficoll-
Paque solution was layered under the cell suspension. The samples were then centrifuged
for 15 min at 800xg at RT without brake. The live cells floating on the top of the high-
density solution were transferred to another tube, washed twice with the growth medium
and used for subsequent procedures.
- OT-II transgenic T cell activation assay
RBC depleted splenocytes and LN cells from OT-II mice were pooled and stained with
anti-CD4 FITC Ab (for positive selection of transgenic CD4 T cells), anti-CD8 PercP Ab
(to make sure that all CD8 cells, that also could respond to OVA peptide are excluded)
and anti-CD44 PE (to exclude activated cells). The CD4+ cells were sorted and labelled
with CFSE (as described above). For activation, LAG-3 positive or LAG-3 negative
APCs were loaded with various concentrations of 323-339 OVA peptide for 2 hours (50
000 cells per well, in 96-well round bottom plates), and 25 000 of CFSE labelled reporter
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CD4 T cells was added per well. T cell proliferation was monitored by CFSE dilution
measurement for 6 days.
3.3. Mice
BalbC HARLAN Italy, San Pietro al Natisone, Italy
C57BL6 HARLAN Italy, San Pietro al Natisone, Italy
LAG3 knock-out Dr. D. A. Vignali, Department of
Immunology, St. Jude Children’s Research
Hospital, Memphis, TN
OT-II Charles River Laboratories, France
RAG/CγC dko Institute for Research in Biomedicine mouse
facility, Bellinzona
In all the experiment the mice we age and sex matched.
3.3.1 Animal techniques
- collection of organs
6-12 weeks old mice were sacrificed by CO2 inhalation and spleen and LN (mesenteric,
inguinal, axillar and popliteal) were removed.
 -reconstitution of lymphopenic mice
RAG/CγC double ko mice were used as recipients. These mice have no B, T nor NK
cells. 5 x 106 of total C57BL6 LN cells were injected in tail vain of sublethally (400 rads)
irradiated recipient mice. 
- LPS injections
5ug of LPS (in 200ul of PBS) per mouse was injected intraperitonally (i.p.).
63
4.  RESULTS AND DISCUSSION
 4.1. Generation and characterization of monoclonal antibodies
against mouse LAG-3
In order to study the expression pattern and function of LAG-3 we produced a number of
monoclonal antibodies (mAbs) against mouse LAG-3. Lewis rats were immunized by
injection into foot pads with LAG-3 transduced rat myeloma Y3 cells. Specific antibody-
producing hybridomas were selected by flow cytometry (surface staining of LAG-3
expressing cell line) and by ELISA with LAG-3hIgG1 fusion protein as antigen. MAbs
produced by selected clones were then epitope mapped using recombinant LAG-3 molecules
consisting of either D1 to D2 (D1-D2) or D1 to D4 (D1-D4) domains, as shown in Figure
4.1.1, and grouped into 2 specificity categories: D1-D2 and D3-D4.
Figure 4.1.1. Screening of anti-LAG3 hybridomas. Recombinant LAG-3 molecules
composed of D1 to D4 (D1-D4) or D1 to D2 (D1-D2) domains (for more information see
section 4.2) in the form of Drosophila culture supernatant (D1-D4) and Drosophila cells
lysate (D1-D2; D2l truncation), respectively, were separated on non-reducing 10% PAGE.
The blots were probed with hybridoma supernatants (various hybridomas are represented by
numbers indicated at the top), followed by goat anti-rat Ig HRP linked conjugate.  Rabbit
polyclonal anti-mouse LAG-3 Ab, followed by goat anti-rabbit HRP conjugate were used as
a positive control (C). Sample blots are shown.
Twelve hybridomas were chosen for further analysis; G15, G21, G23, G30, G31, G35, G37,
G38 which are specific for D1-D2 region and G19, G24, G27 and G40 specific for D3-D4
region.  Some of them (for example G15 and G35) did not perform well in western blot,
likely because they recognize conformational epitope that is lost upon denaturation of the
  2    5    6    8   11  12  15  19  21  23  24  25  27  28  30  31  33  35  37  C    
D1-D4
D1-D2
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Figure 4.1.2. Staining of activated lymph node cells with purified anti-LAG-3 mAbs G15,
G19 and G35. The cells were activated on immobilized anti-CD3 for four days. For analysis
the samples were gated on CD8 T cells from wild type (in blue) or LAG-3 deficient (in red)
mice.
a)
     
b)
EP 1 -G24/G40 EP 2 - G15/23
EP 3 - G 21 EP 4 - G19
EP 5 - G27 EP 6 - G37/G38
EP 7 – 35 EP 8 - 30/31
Figure 4.1.3. Sandwich ELISA was performed with purified monoclonal antibodies
(indicated on the left) presenting the soluble LAG-3 (D1 to D4). Biotinylated antibodies (top)
were used for detection.  w- weak signal, vw- very weak signal.
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samples. The isotypes of mAbs were determined by ELISA (not shown).  Two of them:
G31 and G37 Abs are of IgG2b isotype, the other 10 Abs are IgG2a.
The monoclonal antibodies were purified, biotinylated and their specificity was
ascertained by the ability to stain αCD3 and αCD28 Abs- activated splenocytes from
wild-type, but not from LAG-3 deficient mice, as exemplified in Figure 4.1.2.
Furthermore, sandwich ELISA results showed that at least 8 different epitopes were
recognized by various monoclonal Abs (Figure 4.1.3).
The obtained antibodies were also tested in immunocytochemistry. T cell line stably
transfected with LAG-3 (A5LAG-3 cells, see below) was plated on cover slips,
paraformaldehyde (PFA) fixed and stained with various antibodies. In this type of
application G24 and G37 Abs were working well (Figure 4.1.4)
Figure 4.1.4. Immunocytochemical analysis of LAG-3 expressing T cell line, A5LAG-3
(left and middle panel). Biotinylated G37 and G24 Abs were used for detection, followed
by streptavidin Texas Red.  Non -transfected A5 cells served as negative control (NC),
right panel.
It was also analyzed if the generated monoclonal antibodies were functionally active. For
this purpose A5 cells, an HA-peptide specific T cell hybridoma carrying GFP gene under
the control of minimal IL-2 promoter (Andersen et al., 2001) was used. These cells turn
green upon activation, which can be easily detected by FACS. Figure 4.1.5 shows both
time course and concentration curve of A5 cells’ response to proliferation stimuli.
LAG-3 positive variant of T cell hybridoma (A5) was made by stably transfecting the
cells with a plasmid harbouring LAG-3 cDNA sequence under the control of EF-1a
promoter. A5 LAG-3 cells express high levels of LAG-3 on their surface (Figure 4.1.6).
A5LAG3 A5
G 37 G 24 NC
A5LAG3
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       a) time course        b) dose response
      FL-1           FL-1
Figure 4.1.5. Kinetics and dose response of A5 cells stimulated with αCD3 Ab or by
specific antigen. A5 cell activation can be monitored by the increase in GFP
fluorescence. (a) A5 cells were stimulated with immobilized αCD3 Ab and analyzed at
various time points: 0 (black), 4 (pink), 8 (blue) and 20 (green) hours. (b) A5 cells were
stimulated for 16 hrs with HA peptide pulsed A20 cells (B cell lymphoma). Various
concentrations of peptide were used: 0 (red), 0.1 (grey), 1 (blue), 10 (black) and 100
(green) µg/ml.
Figure 4.1.6. The expression level of LAG-3 on the surface of A5LAG-3 cells. A5 cell
were stably transfected with Lag-3, LAG-3 surface levels were analyzed by staining with
biotinylated mAb G15, followed by Streptavidin-APC. LAG-3 - blue line, negative
control (secondary reagent only) - black line.
When A5 and A5LAG-3 cells were stimulated with APCs pulsed with the relevant
antigen, we observed that the T cells with LAG-3 on their surface showed poor activation
as compared to WT A5 cells (Figure 4.1.7, pink line versus dark blue line). This result is
consistent with the results of similar experiments done by others (Workman et al.,
2002a). The inhibitory effect was very strong (more than 95%), and decreased slightly (to
about 60 %) with increased HA peptide concentrations used for loading of APCs.
A5 A5LAG-3
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Subsequently, it was tested if mAbs against LAG-3 can counteract the activity of
ectopically expressed LAG-3. Indeed, the majority of monoclonal antibodies were able to
efficiently neutralize the inhibitory effect of surface LAG-3. Upon addition of
monoclonal antibodies, the activation levels of A5LAG-3 cells came close to that A5
cells, as shown in Figure 4.1.7.  The strength of ‘neutralizing effect’ did not strictly
correlate with the epitopes recognized by mAbs. The D3-D4 mAbs G24 and G40 were
not very efficient in neutralizing LAG-3 function, but the D3-D4 mAbs G19 and G27
were as efficient as all D1-D2 Abs tested.
Figure 4.1.7. Monoclonal antibodies are able to neutralize inhibitory effect of surface
LAG-3 on T cell activation. A20 cells were pulsed with HA peptide at indicated
concentrations and used to activate A5 or A5LAG-3 cells in the absence or presence of
various mAbs. The activation of A5 cells was not affected by mAbs. The effect of mAbs
on the activation A5LAG-3 cells is shown.
Altogether, the above results indicate that the new mAbs against LAG-3 we generated are
highly specific and are functionally active in vitro. They work in various types of assays
and hence are ideal for investigating LAG-3 expression and function in the immune
system.
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4.2. Production of soluble LAG-3 for structural studies
As insect cells are known to be suitable hosts for heterologous protein expression and
production, we chose Schneider cell line (Schneider, 1972), a cell line derived from
primary cultures of late-stage of Drosophila melanogaster embryos, for the production of
soluble LAG-3.
It was first tested if the LAG-3 consisting of all four extracellular domains (D4t) and its
shorter truncation (D2t) consisting of the two outmost domains can be expressed in
Drosophila SL-3 cells. The coding sequences for D4t (nucleotides 357-1769) and D2t
(nucleotides 357-1122) were amplified from thymus cDNA by PCR and cloned into
pRmHa-3 vector. The important feature of pRmHa-3 vector is the metallothionein (MT)
promoter, which contains heavy metal response elements. This allows for inducible
expression of protein under investigation, upon addition of cadmium or copper, the latter
being less toxic to the Drosophila cells (Bunch et al., 1988).
SL-3 cells stably transfected with pRmHaLAG-3D4t or pRmHaLAG-3D2t plasmid were
treated with CuSO4 for 3 days to induce the production of recombinant proteins. Culture
supernatants as well as cell pellets were collected. The supernatants and cell lysates were
treated with protease inhibitors to prevent protein degradation. Western Blot analysis was
performed to check the levels of the recombinant LAG-3 production.  As shown in Figure
4.2.1, D4t truncation was present in both in cell lysate and in culture supernatant, while
D2t was produced in the cells but could not be secreted. D4t protein migrated with
apparent molecular weight of 53 kDa and D2t product of 25 kDa.
Because LAG-3 D2t was retained inside the cells, two additional short truncations (D2s
encoded by nucleotides 357-1092 and D2l encoded by nucleotides 357-1157) were
constructed. As for D2t, although both of them were produced in SL-3 cells, they were
not secreted into the media (Figure 4.2.2). This indicated that the shorter truncated forms
of LAG-3 do not fold correctly and would not be suitable for further analysis.
At this point we focused on the longer version - D4t of recombinant LAG-3. Its presence
in the SL-3 culture supernatant facilitated subsequent purification.
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Figure 4.2.1.  Western blot analysis of the supernatants (Sup) and cell lysates (Lys) of
pRmHa LAG-3D4t or pRmHaLAG-3D2t stably transfected SL-3 cells after CuSO4
induction. Samples were separated on 12 % PAGE under reducing conditions. The blot
was probed with rabbit polyclonal anti-mouse LAG-3 Ab, followed by goat anti-rabbit
HRP liked Ab.
Figure 4.2.2. Western blot analysis of the supernatants (Sup) and cell lysates (Lys) of
pRmHa LAG-3D2s or pRmHaLAG-3D2l transfected SL-3 cells after CuSO4 induction.
Samples were separated on 12 % PAGE under reducing conditions. The blot was probed
with rabbit polyclonal anti-mouse LAG-3 antibody, followed by goat anti-rabbit HRP
linked Ab.
We chose to affinity purify soluble LAG-3 D4t using one of our monoclonal antibodies.
Ab G40 (IgG 2a) was coupled to CNBr-activated Sepharose 4B to prepare the affinity
chromatography column. The soluble LAG-3 D4t was produced in a batch-wise manner
(1.5 L at a time) and loaded on the G40 affinity column. After each load the absorption to
the column was ensured by Western blot as shown in Figure 4.2.3a. The level of
absorption to the column varied slightly from batch to batch, possibly due to small
differences in speed of loading of the supernatant and/or the amount of protein present in
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the supernatant. After reaching saturation (equivalent to 11 Liters of SL-3 culture),
affinity column was eluted with pH 3.2 Glycine-HCL buffer. The protein content of the
eluted fractions was determined by measurement of Absorbance at 280 nm (A280). LAG-
3 D4t elution profile is presented in Figure 4.2.3b.  Approximately 50 mg of recombinant
protein was obtained.
Figure 4.2.3. The production of soluble LAG-3. (a) The subsequent batches of LAG-3D4t
expressing SL-3 cells culture supernatants (40 µl/lane) were analysed for presence of
soluble LAG-3 by Western blot before (B) and after (A) affinity column. The blot was
probed with rabbit polyclonal anti-mouse LAG-3 Ab, followed by goat anti-rabbit HRP
linked Ab. (b) The elution profile of the column saturated with soluble LAG-3 is shown.
A280 –Absorbance at 280 nm.
To determine the purity of affinity purified soluble LAG-3, samples of different fractions
were subjected to 10% PAGE under reducing conditions followed by staining with
GELCODE® Blue protein stain reagent. Figure 4.2.4 shows that this one step
purification was very efficient; there is hardly any contamination detectable.
The whole procedure was repeated and additional 70 mg of the soluble LAG-3 D4t were
obtained.
There are 5 potential N-linked glycosylation sites in murine LAG-3. And it is known that
heterogenous glycosylation can prevent protein crystallization. To optimize the
conditions for LAG-3 crystallization, we produced a non-glycosylated version of sLAG-3
in addition to wild-type glycosylated form of soluble LAG-3.
First, we tested if tunicamycin - a specific inhibitor of N-linked glycosylation would
work in our culture conditions. As shown in Figure 4.2.5a, the pre-treatment of SL-3
culture before CuSO4 induction is not required, but tunicamycin must be added at the
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Figure 4.2.4. Affinity-purified soluble LAG-3 shows high degree of purity. 2 ug of total
protein per fraction from affinity column-eluted fractions were subjected to 10% PAGE
under reducing conditions. After separation gel was stained with GELCODE Blue Stain
Reagent.
time of induction. When inhibitor was added 3 hrs after induction the glycosylated ‘band’
(the upper band, Figure 4.2.5a) was already visible. There is a clear shift in mobility of
recombinant LAG-3 D4t after tunicamycin treatment, the non-glycosylated LAG-3D4t
migrates at approximately 44 kDa (compared to 53 kDa of glycosylated version).
The above assessment of tunicamycin activity was performed with a quite high
concentration of tunicamycin (5 µg/mL). It was then tested if, for a larger scale
production, lower concentrations of tunicamycin could be used.  Indeed, the
concentration as low as 0.8 µg/ml worked well (Figure 4.2.5b). However, when 0.5
µg/ml of tunicamycin was used the level of inhibition showed variation between
experiments (not shown). Finally, we decided on the 1 µg/ml concentration; at this
concentration no toxic effect was observed on sLAG-3 producing SL-3 cells, the problem
often encountered using Baculovirus expression system involving Sf9 insect cells.
Next, the production of LAG-3D4t was repeated, this time in the presence of
tunicamycin. Before the chromatography purification each batch was checked for
efficient de-glycosylation (Figure 4.2.6, e.g. lane 7 to 9). As its glycosylated counterpart,
non-glycosylated protein efficiently absorbed to the affinity column (Figure 4.2.6 lanes 1
to 6). After column saturation and elution in pH 3.2 Glycine-HCL buffer, the protein
content of the eluted fractions was analysed on 10 % reducing PAGE, followed by
GELCODE staining.
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Figure 4.2.5.  Production of non-glycosylated LAG-3D4t. (a) time course; lane 1-
5ug/mL tunicamycin 5 hrs before induction, lane 2- 5ug/mL tunicamycin at the time of
induction, lane 3- 5ug/mL tunicamycin 3 hrs after induction, lane 4 - no tunicamycin,
lane 5- no induction (b) concentration curve; lane 1- 5ug/mL, lane 2 - 3.3ug/mL, lane 3 -
1.7 ug/mL, lane 4 - 0.8 ug/mL, lane 5 - no tunicamycin, lane 6 - no induction. The
supernatants were separated on 10% PAGE under reducing conditions. The blot was
probed with rabbit polyclonal anti-mouse LAG-3 antibody.
   
Figure 4.2.6.  Western blot analysis of LAG-3D4t expressing tunicamycin treated
Drosophila cultures. Lane 1 – no induction, Lane 2- with induction, Lane 3 – batch 1
before column, Lane 4 – batch 1 after column, Lane 5 – batch 2 before column, Lane 6 –
batch 2 after column, Lane 7 – batch 3, Lane 8 – batch 4, Lane 9 – batch 5. All batches
were tunicamycin treated. The supernatants were separated on 10% PAGE under
reducing conditions. The blot was probed with rabbit polyclonal anti-mouse LAG-3
antibody.
Figure 4.2.7 includes the elution profile (a) and PAGE analysis (b) of the non-
glycosylated soluble LAG-3 D4t.  About 55 mg of pure protein were obtained from 12
liters of SL-3 culture. The ‘large-scale’ production procedure of non-glycosylated LAG-
3D4t was repeated and additional 80 mg of purified protein were obtained (not shown).
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Figure 4.2.7. The production of non-glycosylated soluble LAG-3. (a) chromatography
column protein elution profile (elution was carried out at pH 3.2) and (b) GELCODE
Blue Stain Reagent staining. 2 ug of total protein per fraction from eluted fractions were
subjected to 10% PAGE under reducing conditions. C- glycosylated soluble LAG-3 was
used as control.
Overall, Drosophila SL-3 expression system established in the course of this work
proved to be an efficient way to produce soluble LAG-3  (composed of four extracellular
domains) in two flavors: glycosylated and non-glycosylated.
In general Drosophila cells are easy to maintain in culture and have the advantage over
the mammalian cell expression system in that they grow optimally in room temperature
and do not require CO2 incubator.
The purified soluble LAG-3 proteins are now used in structural studies, which are done in
collaboration with Dr. Roy Mariuzza (Center for Advanced Research in Biotechnology,
University of Maryland Biotechnology Institute, Rockville, USA).
Interestingly, soluble LAG-3D4t behaved as a dimer in size exclusion chromatography.
The molar mass of LAG-3D4t calculated by amino acid composition is 43.7 kDa;
however, the molar mass from MALDI (matrix assisted laser desorption/ionization) mass
spectrometry was ~ 50.1 kDa, exhibiting several prominent peaks ranging from 49.4 to
51.6 kDa as a result of differences in the extent of glycosylation.
Unfortunately, all the efforts to crystallize this form of LAG-3 have failed, may be due to
molecular heterogeneity caused by uneven glycosylation.
a) b)
0
0.5
1
1.5
2
2.5
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Fraction
A
2
8
0
Fraction
60
50
40
     14     16     18     20     23     26    29 kDa
 C
74
Pleasingly, however, the non-glycosylated soluble LAG-3 also behaved as dimer and
respective MALDI analysis revealed, as expected, more homogenous molecular species
(~ 44.9 kDa).
Attempts to crystallize non-glycosylated LAG-3D4t in its free and MHC class II bound
forms are underway. If successful the detailed structural information can tell us more
about LAG-3 itself as well as LAG-3–MHC class II interaction(s). In addition this
structure may help us to understand how CD4, a well-known TCR co-receptor and a
relative of LAG-3, binds to MHC class II – one of the key interactions in the immune
system but of so low affinity that good quality complexes are extremely difficult to
obtain.
Biochemical analysis of soluble protein showed that in solution LAG-3 forms stable
dimers. This observation strongly suggests the presence of such dimers on cell surface.
LAG-3 dimers on T cells could augment its avidity for MHC class II, or other ligand, and
thereby enhance LAG-3 mediated signaling. This notion is supported by recent data by Li
and colleagues. Their cross-linking studies of LAG-3-transduced T cell hybridoma
showed that LAG-3 can form dimers and even oligomers at the cell membrane (Li et al.,
2004). Human LAG-3 studies have previously also suggested that LAG-3 might be
expressed as a dimer, but no biochemical support for this hypothesis has been presented
(Huard et al., 1997).
Furthermore, as analysed by Western blot, soluble LAG-3 isolated from splenic culture
supernatants (described in section 4.4 of this report) closely approached, in terms of
molecular weight, the recombinant LAG-3 composed of 4 extracellular domains
(glycosylated form). This observation supports the ‘proteolytic processing’ rather than
‘alternative splicing’ mechanism of soluble LAG-3 generation.
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4.3.  LAG-3 on naïve, effector and regulatory T cells.
Although there have been a number of reports about LAG-3, its function in the immune
responses has remained enigmatic. The discrepancies between a human and a mouse
system led to confusion. LAG-3 function as negative regulator of T cell activation
concluded from studies with human cells was not confirmed in LAG-3 knock-out mice
(Hannier et al., 1998; Huard et al., 1994b; Miyazaki et al., 1996). While the function for
LAG-3 in NK cell killing, suggested from LAG-3 knock-out studies was not supported
by evidence from human cells (Huard et al., 1998; Miyazaki et al., 1996). Also the later
more detailed analysis of LAG-3 deficient mice was not consistent (Workman et al.,
2004; Workman and Vignali, 2003).
Having new tools for LAG-3 analysis at hand, we decided to first re-examine the
expression pattern and function of LAG-3 on mouse T cells.
4.3.1. Expression of LAG-3 on CD4 and CD8 T cells and its role in
homeostasis
First, we looked at the LAG-3 expression on the surface of CD4 or CD8 T cells over time
after CD3 triggering. Figure 4.3.1 shows the time course of LAG-3 expression on
activated T cells. Freshly isolated mouse splenic and lymph node T cells do not express
LAG-3 (not even approximately 2%, as reported by Workman and colleagues (Workman
et al., 2002a)). It appears on the surface of T cells within 24 hours of CD3 engagement
and reaches plateau on day 3 of activation (Figure 4.3.1 a and b).
Furthermore, the levels of LAG-3 were slightly (approximately 2 fold) but consistently
higher on CD8 T cells than on CD4 T cells. Similar observation has been reported by
Huard and colleagues working with human PHA blasts (Huard et al., 1994a). This
difference in LAG-3 expression pattern may be due to the fact that Lag-3 gene lies within
CD4 locus (Bruniquel et al., 1997) and its promoter may be partially silenced when CD4
gene is activated.  In addition, upon CD8 T cell triggering with the relevant peptide,
LAG-3 co-capped with CD3 much more efficiently then in case of activated CD4 T cells
(Hannier and Triebel, 1999). The observation that CD8 cells express more LAG-3 on
their surface is difficult to reconcile with LAG-3 being the only MHC class II ligand.
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But, LAG-3 function on CD8 T cells has not been extensively analyzed as the LAG-3
studies concentrated more on MHC class II restricted CD4 cells.
How could LAG-3 play a role in class I restricted responses?
Frederic Triebel, in his recent review, suggested the model of molecular interactions
between a CD8 T cell and APC, in which he considers LAG-3 as independent co-receptor
(Figure 4.3.2), supporting the idea that LAG-3 does not interfere with CD4-MHC class II
interactions but rather directly inhibits T cell activation through intracellular signaling
(Triebel, 2003). However, it is possible that a ligand other than MHC class II could be
involved in LAG-3 function on CD8 cells.
a)
b)
Figure 4.3.1. Activated T cells express LAG-3 on their surface. (a) Lymph node cells
were activated on immobilized αCD3 Ab for 24 hours. Triple staining (CD4/CD8/LAG-
3) before and after activation is shown. (b) Splenocytes were cultured on αCD3 coated
plates for indicated times, staining was done as in (a) and the samples were gated on CD4
or CD8 T cells.
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Figure 4.3.2. LAG-3 -MHC class II interactions. Shown are the consequences of LAG-3
interactions when a CD8 T cells meets an APC. Two motifs of the intraplasmic region
potentially involved in signaling are shown (from (Triebel, 2003). In such scenario
signaling downstream from LAG-3 would interfere with signaling pathways activated by
TCR tiggering.
Then, we looked at the kinetics of LAG-3 down-regulation and asked if continuous
stimulation is necessary for surface LAG-3 expression. In order to see how long LAG-3
persists on the surface of T cells after removal of proliferation stimulus, purified T cells
were activated on immobilized anti-CD3 and anti-CD28 Abs for 3 days, then collected,
washed and cultured in normal growth medium supplied with IL-2. As shown in Figure
4.3.3, after removal of the stimulus, T cells kept high levels LAG-3 on their surface for at
least 24 hours; followed by about 50% loss after 4 days, and after 7 days going down to
Figure 4.3.3. Surface expression of LAG-3 on activated T cells after removal of
proliferation stimulus. Purified T cells were activated on immobilized anti-CD3 and anti-
CD28 for 3 days and transferred to IL-2 supplied growth medium. The time of transfer is
indicated by the dotted line.
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the level before activation. Therefore, it can be concluded that continuous stimulation is
required to maintain high levels of surface LAG-3.
Until now, all of the studies on murine LAG-3 demonstrating its presence on T cells were
carried out in vitro.  In an attempt to find LAG-3 in vivo, we looked at homeostatically
expanding T cells. Using our new monoclonal antibodies we show that LAG-3 appears
on the surface of T cells undergoing homeostatic proliferation in lymphopenic hosts. LN
cells from normal mice were transferred into sublethally irradiated recombinase
activating gene-2 and common cytokine receptor γ chain (RAG 2/CγC) double ko mice
(Mazurier et al., 1999).  RAG/CγC are suitable hosts for the lymphocyte reconstitution
experiments, because they are completely alymphoid (they lack T, B as well as NK cells).
After 10 days spleen cells were analyzed by FACS. Normal ratios of CD4 to CD8 T cells
were found in reconstituted mice (Figure 4.3.4). The majority of them were blasting,
indicating active proliferation. LAG-3 was clearly detectable on about 50% of blasts
(Figure 4.3.4).  This data suggests a role for LAG-3 in homeostasis. In fact, the function
of LAG-3 during T cell homeostasis was recently implied from the experiments involving
LAG-3 deficient mice, but the surface expression of LAG-3 in wild type animals has not
been demonstrated. Workman and Vignali reported that, CD4+ and CD8+ LAG-3
deficient T cells show enhanced homeostatic expansion in the spleen of lymphopenic host
(2.6 fold), which was abrogated by ectopic expression of WT LAG-3 (Workman and
Vignali, 2005).  Based on the findings that the spleens of 16 weeks old LAG-3 ko mice
not only have increased numbers of T cells (2 fold), but also of B cells, granulocytes,
macrophages and DCs they go on to suggest that cells that express LAG-3 (that is T cells)
regulate the expansion of cells that do not (other leukocyte subtypes). Of particular
interest is the observation that there was a substantial increase in splenic pDCs (4 fold) in
LAG-3 ko mice.  In the light of the findings presented in this thesis, especially the high
expression of LAG-3 on activated B cells and pDCs (see section 4.5), their data could be
reinterpreted as indicating LAG-3 mediated regulation of B cell and DC homeostasis.
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Figure 4.3.4. CD4 and CD8 T cells undergoing homeostatic expansion express LAG-3.
LN cells from normal mice were transferred into a lymphopenic recipient. After 10 days,
splenocytes of reconstituted and WT mice were analyzed for LAG-3 expression. Analysis
of large blasts is presented. CD4+ and CD8+ populations are shown in left side panels.
LAG-3 staining of CD8 gated cells is shown in red (secondary reagent control in grey), of
CD4 gated cells in blue (secondary reagent control in black) and of CD8-CD4- cells in
green (right side panels). The small cells do not express LAG-3 (not shown). The data are
the representative of two independent experiments.
4.3.2. Is LAG-3 required for T reg suppressive activity?
The experiments involving ectopic expression of LAG-3 on A5 cells (section 4.1)
suggested that this molecule has an immunoregulatory function on T cells, in agreement
with reports by others (Hannier et al., 1998; Huard et al., 1996; Workman et al., 2002a);
LAG-3 can act as a negative regulator of T cell activation. Interestingly, it was recently
proposed that LAG-3 controls T cell function not only intrinsically (on the surface of
effector T cells) but also extrinsically by its presence on regulatory T cells. In the recent
report Huang and colleagues suggested that LAG-3 is important for the suppressive
function of regulatory T cell subpopulation (Huang et al., 2004).
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Figure 4.3.5. Non-activated regulatory T cells do not express LAG-3 on their surface.
Freshly isolated or αCD3 and αCD28 activated (2 days) splenocytes from WT mice were
stained for CD4, CD25 and LAG-3. The analysis was done on CD4 gated cells. The
CD25+ population representing about 9% of total CD4 population  (left panel) is LAG-3
negative.
Figure 4.3.5 shows that the CD25+ CD4+ T reg cells freshly isolated from a mouse are
LAG-3 negative. In contrast, most of CD4 T cells activated with anti-CD3 and anti-CD28
Abs for two days stain positively for LAG-3. However, at this stage all activated cells
express CD25 and T regs cannot be distinguished anymore. To verify LAG-3 expression
on T regs, the experiment was repeated with purified naïve/effector (CD4+CD25-) and
regulatory (CD4+CD25+) T cell populations. The purified cells were additionally
labelled with CFSE allowing for easy detection of their proliferation.
Mouse regulatory T cells when stimulated and cultured alone show anergic phenotype,
they proliferate poorly after TCR stimulation, when compared to effector T cells (Figure
4.3.6 a and b). This is the consequence of their dependence on exogenous IL-2, to such a
degree that CD4+ CD25+ T cells are absent from IL-2 deficient mice (Papiernik et al.,
1998). Yet, the regulatory cells that managed to proliferate up-regulated surface LAG-3,
just like the effector population. It could be argued that this population resulted from
contaminating effector T cells, unfortunately without a specific marker for T regs
available, it is impossible to rigorously examine it. However, when T regs were mixed
with non-labelled effector cells in 1 to 4 ratio and stimulated via their TCR, they
proliferated just as well as effector cells alone and expressed the same levels of surface
LAG-3 (Figure 4.3.6 c).
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      a)    b) c)
Figure 4.3.6. LAG-3 expression on regulatory versus effector T cells. The purified LN
and spleen (a) effector (CD4+CD25-) and (b) regulatory (CD4+ CD25+) T cell
populations were CFSE labeled and independently stimulated with soluble αCD3. After 4
days LAG-3 surface staining was performed.  (c) CFSE labeled regulatory T cells (blue)
were mixed with non-labeled effector T cells (red) in 1 to 4 ratio, respectively, and
stimulated with soluble αCD3 for four days. LAG-3 staining and T regs CFSE dilution
profile are shown.
In conclusion, consistent with the results of Huang et al., we could show that natural
CD4+ CD25+ T regs express LAG-3 upon activation, which is significantly enhanced in
the presence of effector cells. Naïve CD4+ CD25+ regulatory cells have no surface LAG-
3, although reportedly they show significantly higher levels of LAG-3 mRNA (Huang et
al., 2004). This discrepancy could be explained by the possibility of intracellular LAG-3
storage. Furthermore, after activation (monitored by CFSE dilution) the level of LAG-3
on T regs is the same as on classical effector cells, suggesting that LAG-3 cannot be used
as a marker to distinguish T reg population.
To assess whether LAG-3 is indispensable for the suppressive function of regulatory T
cells, we subjected WT as well as LAG-3 deficient T cells to the standard in vitro
suppressor assay. The CFSE labelled WT effector T cells were cultured alone or were
mixed in 1 to 1 ratio with WT or LAG-3-deficient unlabeled regulatory T cells, and the
proliferation of effector cells was followed by CFSE dilution. As shown in Figure 4.3.7,
the WT and LAG-3 deficient T regs were able to suppress the proliferation of WT
effector T cells to the same extent suggesting that LAG-3 is dispensable for suppressor
activity of T regs. The suppressive effect of WT and LAG-3 KO T regs was observed
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Figure 4.3.7.  The deletion of LAG-3 does not affect the suppressive activity of T regs.
CFSE labeled WT effector cells were mixed with unlabeled WT effector cells (in red) as
controls, WT Tregs (in blue) or LAG-3 deficient Tregs (in green) in 1 to 1 ratio. The cells
were stimulated with 0.1ug/ml of anti-CD3 in the presence of irradiated APCs for 4 days.
The effector cell proliferation was followed by CFSE dilution.
over a range of anti-CD3 concentrations (0.1 ug/ml to 5 ug/ml) and was independent of
LAG-3 expression on T cells as also LAG-3 deficient effector cells could be suppressed
by both T reg variants (not shown). Furthermore, the addition of monoclonal anti-LAG-3
antibodies to WT T regs also did not affect their activity (not shown).
The above results are clearly in disagreement with the report by Huang and colleagues
(Huang et al., 2004). This discrepancy can be partially explained by different assays and
models used. Huang et al. used a very specific in vivo model and non-standard in vitro
assays. Also they do not clearly define ‘regulatory ‘ population and the effects they
observed were generally quite weak.
Our results do not support the notion that LAG-3 is a specific marker for T regs. Any
type of in vitro activated T cell becomes strongly LAG-3 positive.
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4.4. T-cell induced expression of LAG-3 on B cells
‘Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced
by T cells’ Kisielow M., Kisielow J., Capoferri-Sollami G. and Karjalainen
K.  2005.  Eur.J. Immunol. 35: 2081-2088.
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4.4.1 Analysis of B cells - supplementary data
To complete the kinetic analysis of LAG-3 expression on B cells, we looked at the rate of
down-regulation of LAG-3 on this lymphocyte subpopulation.
LAG-3 expression on the surface of B cells peaks on day 3 to 4 of culture with activated
T cells and stays on at least till day 6. Purified B cells need both the proliferation stimulus
(for example, provided by BCR triggering together with anti-CD40 help) and a soluble
factor produced by T cells in order to express LAG-3 on their surface.
After withdrawal of proliferation stimuli LAG-3 disappears from the surface of B cells
quickly, as demonstrated by the following experiment. B cells were purified by cell
sorting from splenocyte cultures 3 days after stimulation with αCD3 and αCD28 Abs.
Figure 4.4.1. Down-regulation of surface LAG-3 on B cells after removal of proliferation
stimuli. CD19 positive cells were sorted from splenocyte cultures activated for 3 days on
immobilized αCD3 and αCD28 Abs, and resuspended in the normal growth medium
(blue line) or in the day 3 activated splenocyte culture supernatant (pink line). LAG-3
levels were determined by surface staining with αLAG-3 mAb G15.
Purified B cells were then transferred to normal growth medium or kept in the
supernatant collected from day 3 cultures from which B cells were sorted (containing the
soluble factor(s) needed). LAG-3 surface expression of the purified B cells was followed
over time.
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Unlike T cells, which display high surface LAG-3 for at least 24 hrs after removal of
proliferation stimulus (Figure 4.3.3), B cells loose surface LAG-3 within hours. After 4
hours ‘off-stimulus’ B cells show only 50% of the initial amounts of LAG-3 and after 8
hours almost all surface LAG-3 is gone (Figure 4.4.1). Thus the rate of LAG-3 down-
regulation is much faster for B cells than for T cells, as T cells needed four days to reduce
their LAG-3 surface expression by half. The soluble factor alone provided in the
supernatant of activated splenocytes, that is responsible for up-regulation of LAG-3 on B
cells, can delay surface LAG-3 down-regulation, but only to a small extent (about 30%).
These results suggest that proliferation stimulus is required not only for up-regulation of
LAG-3 on B cells, but also to keep LAG-3 surface levels up.
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4.5. Characterization of LAG-3 expression on dendritic cells.
In order to comprehensively describe the expression pattern of LAG-3 in the immune
system we also looked at various subsets of DCs.
First, two DC subsets of the spleen; CD8+ (‘lymphoid’) and CD8- (‘myeloid’) cells were
analyzed for LAG-3 expression. The isolated cells were cultured in the normal growth
medium in the absence or presence of various stimuli: TNF-α, LPS, anti-CD40 Ab or
combination of all three (mix). The two DC populations were defined using CD11c and
CD8 as markers (Figure 4.5.1 a). CD11c/CD8/LAG-3 triple staining (Figure 4.5.1 b)
showed that freshly isolated splenic CD8+ or CD8- DCs do not express LAG-3 on their
surface. After 24 hours in culture without any stimulus, the subset of CD8- DCs up-
regulated LAG-3 while CD8+ DC fraction did not. The LAG-3 expression on CD8- DC
subset increased even more upon treatment with various stimuli, of which LPS was most
effective. LAG-3 expression on CD8- without any stimulus is likely the consequence, of
integrin-mediated DC maturation caused by adhesion of DCs to plastic.
Interestingly, none of the stimuli induced LAG-3 expression on CD8+ DCs and the
majority of non-DC population remained negative as well. Staining of B7.2, a molecule
known to be up-regulated after DC stimulation, confirmed that both DC subsets were
activated (not shown).
The observation that LPS can induce expression of LAG-3 on CD8- DCs in vitro was
supported by a set of in vivo experiments. C57BL6 mice were injected i.p. with LPS. This
treatment was shown to induce DC maturation in the spleen (De Smedt et al., 1996).
When both DC subsets, CD11c+CD8+ and CD11c+CD8-, were isolated from LPS
treated mouse, only the CD8- fraction showed higher levels of LAG-3 compared to DC
obtained from untreated animals (Figure 4.5.2).
CD8- DCs are widely distributed in both lymphoid and non-lymphoid tissues, while the
CD8+ DCs are found in the lymph nodes and spleen, and in the thymus where they
predominate (Steinman and Inaba, 1999; Vremec and Shortman, 1997). Considering the
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b)         CD8- DC          CD8+ DC            non-DC population
     LAG-3     →
Figure 4.5.1 CD8- DCs express LAG-3 upon activation. Spleen cells were enriched for
DCs on Opti-prep® gradients and cells were cultured in the presence or absence of
indicated stimuli. (a) CD11c/CD8 staining used to classify DCs (b) LAG-3 staining on
DC subpopulations (mAb G15) is shown in red, isotype control in black.
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            LAG-3   →
Figure 4.5.2.  CD8- DCs up-regulate LAG-3 on their surface upon LPS treatment in vivo.
Balb/c mice were injected (i.p) with LPS (25 µg/ mouse) and LAG-3 staining was
performed on spleen DCs after 24 hours. LAG-3 staining is shown in grey (dotted line),
isotype control in black (solid line).
absence of LAG-3 on CD8+ DCs, as well as on thymic T lymphocyte populations
(Workman et al., 2002b), one could infer that LAG-3 is not important for developmental
events in the thymus; consistent with the observations that positive and negative selection
of T cells appeared normal in LAG-3 deficient mice (Miyazaki et al., 1996).
Perhaps the most striking biological difference between CD8+ and CD8- DC populations,
however, is the ability of the CD8+ DCs to induce Th1 biased cytokine response in
reactive CD4 T cells, whereas CD8- DCs tend to induce a Th2–biased response in vivo
(reviewed in (Ardavin, 2003; Shortman and Liu, 2002)). Yet, both DC populations are
capable of inducing CTL responses and protective antiviral immunity in vivo (Ruedl and
Bachmann, 1999). Identification of LAG-3 on CD8-, but not CD8+ DCs, suggests that
LAG-3 on DCs might play a role in Th2 biased responses, B-cell activation and
plasmablast differentiation.
Subsequently, we also analyzed DC populations present in the LN. After enrichment
procedure, dermal, epidermal, direct bone-marrow immigrants, and plasmacytoid DCs
(pDCs) were distinguished by staining with CD11c and CD40 Abs ((Ruedl et al., 2000)
and C. Ruedl personal communication).
CD8-
CD8+
  control mouse LPS-treated mouse
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Figure 4.5.3. LAG-3 expression on different subpopulations of LN dendritic cells ex vivo.
CD11c/CD40/LAG-3 surface staining was performed on peripheral LN population
enriched for DC by Opti-prep® gradient.  G15 mAb was used for LAG-3 staining. LAG-
3 – grey line, isotype control- black line.
As shown in Figure 4.5.3 freshly isolated murine plasmacytoid DCs (CD11c int CD40
neg) stained positively for LAG-3, while dermal (CD11c int CD40 high) epidermal
(CD11c high CD40 high) and bone marrow DCs (CD11c high CD40 int) did not. It must
be mentioned, however, that intensity of LAG-3 staining of ex vivo plasmacytoid cells,
varied from experiment to experiment.
Further analysis performed on purified plasmacytoid, dermal and epidermal DCs revealed
that pDCs increased their LAG-3 surface levels 100-fold upon stimulation with a Toll
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 Bone -marrow DCs
Dermal DCs
Epidermal DCs
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like receptor 9 (TLR 9) ligand CpG (Figure 4.5.4) (Hemmi et al., 2000). Dermal and
epidermal DCs were unaffected by this treatment.
Figure 4.5.4.  Plasmacytoid DCs up-regulate LAG-3 expression upon stimulation with
CpG. Plasmacytoid, dermal and epidermal DCs were sorted from LN based on CD11c
and CD40 staining as shown in Figure 4.5.3. Purified cells were stimulated with CpG
1826 (Ballas et al., 2001) over-night. LAG-3 staining was performed with mAb G15
shown in blue; isotype control shown in black.
The presence of LAG-3 on pDCs suggests that this surface molecule might be involved in
anti-viral responses. pDCs, also called interferon-producing cells, circulate as precursor
cells in the blood or reside as immature cells in all lymphoid organs. They are the main
source of type I interferons in response to viral infection (Asselin-Paturel et al., 2001).
Type I interferons in turn, induce resistance to viral replication in all cells. The additional
observation, supporting the involvement of LAG-3 in fighting viral infections, is that (as
presented in section 4.3) the activated CD8 T cells (the professional killers of infected
cells) show the highest levels of LAG-3 among all leukocyte populations examined.
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H
100 101 102 103 104
FL4-H 10
0 101 102 103 104
FL4-H
freshly isolated CpG stimulated
Plasmacytoid DCs
Epidermal DCs
Dermal DCs
LAG-3 LAG-3
100
4.6. Indications for a role of LAG-3 in APC function.
Since we were able to detect LAG-3 on the surface of activated APCs (DCs as well as B
cells) we wondered whether it is important for APC function.  To address this question,
we generated LAG-3 positive A20 B cell lymphoma line via retroviral transduction (Fig
4.6.1).
      LAG-3
Figure 4.6.1. A20 cells stably transduced with Lag-3 express high levels of surface
LAG-3, as detected by surface staining with mAb G15. A20LAG-3 - blue line, A20 cells
– black line, negative control- shaded area.
A20 and A20LAG-3 cells were then loaded with increasing concentrations of HA-peptide
and used to activate HA-specific CD4 T cell hybridoma – A5 cells (described in more
detail in section 4.1).  At lower peptide concentrations and for all the time points tested (4
to 14 hours) the higher percentage of A5 cells was activated by A20LAG-3 cells than by
A20 cells transduced with an empty vector (Figure 4.6.2), indicating that A20 cells
expressing LAG-3 are more efficient in triggering T cell activation. At high peptide
concentration and increased stimulation times, however, the effect was abolished, likely
due to saturation of the system. These experiments hinted that ectopic expression of high
levels of LAG-3 on the surface of B cells can indeed enhance their function as antigen
presenting cell.
We then turned to a more physiological situation, that is the ex vivo B cells and examined
their potential to activate antigen specific T cells. In order to obtain LAG-3 positive and
LAG-3 negative B cells, splenic cells from WT or LAG-3 deficient mice were activated
on immobilized anti-CD3 and anti-CD28 Abs for 3 days. After this time of culture WT B
cells express LAG-3 on their surface (Figure 4.6.3). Live cells were isolated using Ficoll-
PaqueTM density separation and loaded with various concentrations of OVA peptide.
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Figure 4.6.2. T cell activation by relevant peptide presented by A20 and A20LAG-3 cells.
B cells loaded with HA peptide at indicated concentrations and used to activate A5 cells
for varying times. The level of T cell activation was assessed by the percentage of green
cells.  The degree of T cell activation by A20LAG-3 cells is shown in blue. The level of
T cell activation by A20 cells transduced with empty pLXSP vector (A20vec) is shown in
pink.
 Figure 4.6.3. B cells in co-culture with activated T cells express intermediate levels of
LAG-3 on their surface. Day 3 Abs activated splenocyte cultures were stained with anti
CD-19 (a B cell marker) and anti-LAG-3 Abs. Both LAG-3 deficient (left panel) and WT
(right panel) mouse cells cultures are shown. In both cultures the large majority of cells
are B cells; T cell probably die quicker by apoptosis under these efficient stimulatory
conditions.
Since the activation state of APCs strongly affects the quality of T-B cell interactions, we
also made sure that the levels of co-stimulatory molecules on the surface of LAG-3
positive and LAG-3 negative presenting cells do not differ. As shown in Figure 4.6.4,
LAG-3 positive and LAG-3 negative B cells show the same levels of B7.1, B 7.2 and
MHC class II. The levels of all three molecules are increased as compared to non-treated
splenocytes, making them potent antigen presenting cells.
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Figure 4.6.4. LAG-3 positive (green line) and LAG-3 negative (blue line) B cells show
the same level of activation. Day 3 anti-CD3 and anti-CD28 activated splenocytes (the
same culture as in Figure 4.6.4) were stained with anti-B 7.1 (left panel), anti-B7.2
(middle panel) and anti- MHC class II (right panel) Abs. Both LAG-3 positive and LAG-
3 negative B cells show increased levels of expression of these activation markers as
compared to non-treated splenocytes (red line).
The peptide-loaded B cells were then used to activate CFSE labeled OVA-specific
transgenic CD4 T cells, isolated from OT-II mice (Barnden et al., 1998). After 6 days T
cell proliferation was determined by CFSE dilution, as shown in Figure 4.6.5a. The
strength of the response of transgenic T cells was dependent on the OVA peptide
concentrations, over a wide range.
Interestingly, at low peptide concentration (0.01 µM), LAG-3 deficient B cells were less
efficient in triggering T cell proliferation; only 50% of T cells activated by LAG-3
deficient B cells divided, while more than 94% T cells divided when they were activated
with LAG-3 positive B cells. At higher peptide concentration (0.1uM), the proliferation
of T cells activated by LAG-3 deficient B cells was also clearly delayed, but much lower
percentage of cells remained undivided (Figure 4.6.5 b).
When presenting cells were flooded with the OVA peptide (1uM), the difference in
antigen presentation by LAG-3 positive and LAG-3 negative B cells was not observed.
This peptide concentration, however, led to the over-stimulation of T cells and increased
T cell death, unlikely resembling a healthy in vivo activation process.
The observations that B cells expressing LAG-3 were more efficient in stimulating
antigen specific T cell proliferation than cells lacking LAG-3 shows that LAG-3 surface
expression can affect T cell triggering in trans.
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Figure 4.6.5.  Surface expression of LAG-3 by B cells affects their ability to activate T
cells.  (a) OVA–specific, CFSE labelled CD4 T cells were activated with LAG-3 positive
(in blue) or LAG-3 negative (in red) B cells loaded with various concentration of OVA
peptide. Peptide concentration used to activate B cells is indicated in µM. (b) Stimulation
of T cells with LAG-3 KO B cells loaded with 0.01 uM or 0.1 uM OVA peptide results in
higher percentage of non-proliferating T cells as compared to WT B cells, the error bars
represent standard deviation among triplicates.
Whether LAG-3 enhances Ag presentation, acts as a novel co-stimulatory molecule or
stabilizes the immunological synapse remains to be clarified. As LAG-3 is known to form
homodimers, the interaction of LAG-3 on APCs with LAG-3 on T cells can be
considered as a possible mode of action.
Nevertheless, the above data indicates the LAG-3 involvement in APC function.
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5. GENERAL DISCUSSION AND FUTURE PROSPECTS
At the beginning of this study LAG-3 was considered to be a T and NK cell specific
molecule, involved in negative regulation of T cell responses. The work presented here
shows that LAG-3 expression in the immune system of a mouse is much broader. B cells
and DCs (especially pDCs) can be induced to express LAG-3 and LAG-3 positive B cells
are better APCs. These findings indicate a more complex role for LAG-3 in the immune
system possibly also as a novel co-stimulatory molecule. One of the practical benefits of
this work could be a new immunization protocol involving LAG-3 transfected APCs.
Consistent with this idea, soluble LAG-3 has been previously shown to be a potent
immunostimulant for inducing antigen- or tumor-specific CTL and CD4 Th1 responses
(El Mir and Triebel, 2000; Prigent et al., 1999).
LAG-3 expression on B cells is mediated by a soluble factor. Unfortunately, we have
failed to identify this factor among the known cytokines we tested. More intensive studies
are required to solve this issue. Potentially, it is a novel lymphokine involved in T-B cell
communication. Identification of a T cell line producing this factor would greatly
facilitate subsequent analysis.
It is clear that MHC class II is a ligand for LAG-3. However, since activated CD4 and
CD8 T cells, NK cells and APCs are all positive for LAG-3 it can be hypothesized that
LAG-3 has alternative ligand(s). To research this area one could produce LAG-3
immunoglobulin (Ig) fusion proteins and use these as specific reagents in flow cytometry
and in immunohistology to detect any binding to cells or tissues derived from MHC class
II deficient mice. Further analysis could then lead to the characterization of the new
putative ligand(s).
The potential multiple roles of LAG-3 in the immune system are further emphasised by
the fact that LAG-3 exists not only in membrane bound form but also in a soluble form.
Initially, soluble human LAG-3 was identified in the serum of healthy individuals
(Annunziato et al., 1996). We show that soluble LAG-3, with the approximate molecular
weight of 53kDa, can be easily detected in the supernatant of murine splenocytes
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activated by TCR ligation (results section 4.4 Figure 4). Soluble LAG-3 can be produced
by activated CD4 as well as activated CD8 T cells. It was found in high concentrations in
culture supernatants, reaching 2 ug/ml, as determined by ELISA (data not shown).
Concominantly, Li and co-workers showed that soluble LAG-3 (with the predicted
molecular weight of 54 kDa) is present in the supernatants of splenocyte cultures from
OT-II transgenic mice activated with OVA (Li et al., 2004). Moreover, they detected low
amounts of soluble LAG-3 in the sera of WT mice (~180 ng/ml). Surprisingly, this
amount of serum LAG-3 was also detectable in RAG-1- deficient mice (mice lacking T
cells and B cells), suggesting that NK cells might be the main source of soluble LAG-3 in
these mice. Alternatively, soluble LAG-3 could be produced by DCs  (in particular
pDCs).
Furthermore, in the light of the classical regulatory T cell assay results presented here,
LAG-3 involvement in regulatory T cell function becomes questionable. LAG-3 should
not be used as a specific marker for T cell activation, nor can it provide the means for
distinguishing the regulatory T cell population.
Our results suggest that, indeed T cell function can also be controlled extrinsically by
LAG-3, but when it is expressed on APCs, rather than on T regs.
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